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Abstract
Certain sterol-based cationic lipids demonstrate both anti-inflammatory and antimicrobial characteristics
in addition to their abilities to facilitate gene transfer. These characteristics are particularly suited for
enhancing potential gene therapies of cystic fibrosis (CF) airway disease, a condition characterized by
chronic infections and concomitant inflammation. Unfortunately, however, animal models of CF do not
show the airway disease typically seen in humans, so in vivo efficacies of potential therapies are difficult
to assess. In this work, three mouse models were established to evaluate adeno-associated virus (AAV)
gene transfer in an infected airway environment. Bordetella bronchiseptica RB50 was used in a chronic,
non-lethal respiratory infection model with C57BL/6 mice. Administration of an AAV vector on day 2 of
this infection resulted in an approximate three-fold reduction of reporter gene expression, compared to
that observed in uninfected controls. Postponement of AAV administration to day 14 resulted in an even
greater (eight-fold) reduction in gene expression. Separately, Pseudomonas aeruginosa PAO1 was used to
infect surfactant protein D or surfactant protein A knockout mice to establish acute infections. Reporter
gene expression was approximately ~2.5-fold lower in these infected mice than in uninfected mice, when
AAV was administered on day 2 of infection. Interestingly, when AAV administration was postponed to
day 9 of infection in the surfactant protein D knockout model, partial regain in expression was observed.
In this case, infection resulted in only a two-fold (vs ~2.5-fold) reduction in gene expression. To reverse
these negative effects on gene transfer, six new sterol-based cationic lipids were synthesized and
characterized. Of the six lipids tested, two, budesonide spermine and disubstituted budesonide spermine,
showed particularly promising in vitro activities and were used to establish proof-of-concept efficacy in an
acute infection model. PAO1-infected mice received lipids on day 1 of infection and AAV 24 hours later on
day 2. When reporter gene expression was measured one week later, only a ~1.5-1.9-fold reduction in
gene expression, compared to the ~2.7-fold reduction seen with untreated controls. Results demonstrate
that treatment with dual functioning anti-inflammatory, antimicrobial cationic glucocorticoids can be
coordinated with CF gene therapies to restore loss of transduction efficiency caused by active infection.
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ABSTRACT
COORDINATING GENE THERAPIES OF CYSTIC FIBROSIS AIRWAY DISEASE
WITH ANTI-INFLAMMATORY AND ANTIMICROBIAL
CATIONIC GLUCOCORTICOIDS
Melissa Myint
Scott L. Diamond

Certain sterol-based cationic lipids demonstrate both anti-inflammatory and antimicrobial
characteristics in addition to their abilities to facilitate gene transfer. These characteristics are
particularly suited for enhancing potential gene therapies of cystic fibrosis (CF) airway disease, a
condition characterized by chronic infections and concomitant inflammation. Unfortunately,
however, animal models of CF do not show the airway disease typically seen in humans, so in
vivo efficacies of potential therapies are difficult to assess. In this work, three mouse models were
established to evaluate adeno-associated virus (AAV) gene transfer in an infected airway
environment. Bordetella bronchiseptica RB50 was used in a chronic, non-lethal respiratory
infection model with C57BL/6 mice. Administration of an AAV vector on day 2 of this infection
resulted in an approximate three-fold reduction of reporter gene expression, compared to that
observed in uninfected controls. Postponement of AAV administration to day 14 resulted in an
even greater (eight-fold) reduction in gene expression. Separately, Pseudomonas aeruginosa
PAO1 was used to infect surfactant protein D or surfactant protein A knockout mice to establish
acute infections. Reporter gene expression was approximately ~2.5-fold lower in these infected
mice than in uninfected mice, when AAV was administered on day 2 of infection. Interestingly,
when AAV administration was postponed to day 9 of infection in the surfactant protein D
v

knockout model, partial regain in expression was observed. In this case, infection resulted in only
a two-fold (vs ~2.5-fold) reduction in gene expression. To reverse these negative effects on gene
transfer, six new sterol-based cationic lipids were synthesized and characterized. Of the six lipids
tested, two, budesonide spermine and disubstituted budesonide spermine, showed particularly
promising in vitro activities and were used to establish proof-of-concept efficacy in an acute
infection model. PAO1-infected mice received lipids on day 1 of infection and AAV 24 hours
later on day 2. When reporter gene expression was measured one week later, only a ~1.5-1.9-fold
reduction in gene expression, compared to the ~2.7-fold reduction seen with untreated controls.
Results demonstrate that treatment with dual functioning anti-inflammatory, antimicrobial
cationic glucocorticoids can be coordinated with CF gene therapies to restore loss of transduction
efficiency caused by active infection.
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1.0 Introduction
1.1 Cystic Fibrosis
Cystic fibrosis is the most common lethal genetic disorder amongst Caucasians, affecting
approximately 1 in every 2000 people [1]. The disease is a caused by a single defective gene,
specifically a mutated CFTR, which encodes for the cystic fibrosis transmembrane conductance
regulator (CFTR). The CFTR is a transmembrane protein channel that is responsible for
regulating liquid volumes at epithelial surfaces by transporting anions, namely chloride and
bicarbonate anions, across the cell membrane as necessary. In individuals with CF, this protein is
either missing or defective, resulting in osmotic imbalances that produce an unusually thick and
extremely viscous mucus layer at epithelial surfaces (Figure 1.1) [2–4].

Figure 1.1: A depiction of a normal and mutant CFTR protein channel.
Adapted from [5]. Without proper transport of anions, osmotic forces cause a thick and viscous mucus to build up at the
outer cell surface.

Clinical symptoms of this condition arise in several different areas of the body, including
the pancreas, intestines, and reproductive organs. The most serious complications, however,
1

present in the upper and lower airways (Figure 1.2). Progressive respiratory disease causes 95%
of all CF mortalities [6]. Due to conditions of their disease, CF patients are particularly
susceptible to chronic infections by a pathogen, Pseudomonas aeruginosa. By the age of 17,
nearly 70% of CF patients are infected with this opportunistic bacterium, and once acquired, P.
aeruginosa is difficult to completely eradicate from the CF airway. Nearly 80% of CF adults have
chronic P. aeruginosa infections that cannot be eliminated by antibiotic therapy [7]. The
persisting infection results in ongoing inflammation and pulmonary complications that can be
ultimately lethal [8].

Figure 1.2: A schematic comparison of a normal and CF airway.
CF airways are characterized by narrowed and inflamed airways, which are congested with a thick and viscous mucus.

1.2 Gene Therapy for Cystic Fibrosis
Gene therapy is the use of nucleic acids to treat or prevent disease. It offers a promising
therapeutic option for many genetic disorders, particularly those caused by a single defective
gene, like CF. In such instances, restorative function depends on the successful delivery and
expression of only a single gene [9]. Additionally, CF airway disease is especially suited for
treatment by gene therapy due to the ease of accessibility of the target organ and the minimal 510% of normal CFTR expression necessary to correct the phenotype [10]. However, over 20 years
has elapsed since the discovery of the CFTR gene, and still, no viable genetic treatment option
2

exists for curing or alleviating CF airway disease. Major barriers, both physical and
immunological, exist as obstacles for successful gene transfer.

1.3 Barriers to Successful Pulmonary Gene Delivery and Expression
1.3.1 Extracellular Barriers
As a major interface with the external environment, the lungs and conducting airways
have evolved efficient physical barriers by which to prevent penetration of any unwanted foreign
particles and substances. One such barrier, mucociliary clearance, is made possible by a ciliated
epithelium bathed in biphasic layer of airway fluid secretions [11,12]. The cilia are situated in the
aqueous (“sol”) layer, also known as the periciliary layer, where they beat and relax. Above the
sol layer sits a mucus (“gel”) layer composed of high molecular weight glycoproteins, known as
mucins, linked to lipids and proteins. The physical, i.e. viscoelastic and adhesive, properties of
this gel layer allow it to trap inhaled particles, while the beating the underlying cilia facilitate
upward movement for removal of these unwanted substances. Other physical barriers against
foreign particles include a glycocalyx that can prevent gene carriers (or vectors) from binding to
appropriate cell receptors and a general scarcity of these receptors on the apical side of the
epithelium [13].
Sophisticated innate and adaptive immune mechanisms of the respiratory tract also play a
role in preventing successful gene transfer in the airway. Alveolar macrophages eliminate gene
carriers or products either directly by phagocytosis or indirectly by their abilities to recruit other
immune cells as antigen-presenting cells [14]. Other immune cells, e.g. neutrophils, dendritic
cells, and lymphocytes, also can play a role in preventing successful gene transfer in the airway.
These cells are responsible for initiating and facilitating non-specific inflammation as well as
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cellular and humoral immune responses that can target the gene carriers and/or the gene products
themselves.
1.3.2 Intracellular Barriers
Once past the extracellular barriers, genes carriers must then overcome additional
obstacles at the intracellular level. These vectors must be able to penetrate the cell membrane,
either by non-specific or receptor-mediated mechanisms. Typically these mechanisms involve
endocytic pathways facilitated by clathrin-coated pits, lipid rafts, and/or direct fusion with the
membrane [15]. In any case, vectors are typically internalized into endosomes, from which they
must then escape before acidic changes in pH initiate the lysosomal degradation pathway [16].
Unfortunately, additional barriers exist even after endosomal release. Once in the cytosol, vectors
must be able to migrate to the nucleus and penetrate the nuclear membrane for entry, all while
avoiding additional opportunities for degradation by nucleases within the cytoplasm before
reaching this final destination [17].

1.4 Overcoming Barriers to Gene Transfer
Multiple approaches are available to overcome these barriers to effective gene transfer.
The correct choices in gene vector as well as in any pre- or co-treatments with chemical
enhancers can allow desired genes to more easily by bypass host immune responses or physical
barriers preventing proper delivery. Viral vectors are efficient and effective at transferring their
genetic material to desired cell types but tend to be much more immunogenic than their nonviral
alternatives. However, while easy to use and manufacture, nonviral gene carriers are unable to
achieve the efficiencies associated with viral gene carriers. Efforts are ongoing to address the
drawbacks of each type of vector.

4

1.4.1 Cationic Lipids as Chemical Enhancers of Gene Therapy Vectors
One such effort involves the use of cationic lipids, which are able to facilitate delivery of
DNA to cells. Addition of these lipids to DNA forms complexes, known as lipoplexes, that
exhibit lower overall negative charge and easier associations with cellular membranes than
standalone, or naked, DNA is able to. These physiochemical changes allow lipoplexes to shield
DNA from extra- and intracellular nucleases by compacting its size and concealing it within its
lipid bilayers [18]. Neutral lipids, such as cholesterol or dioleoylphosphatidylethanolamine
(DOPE), can be included to aid in the formation of liposomal structures [16]. DOPE is
particularly useful due to its ability to fuse with other lipids at low pH, e.g. in an endosome
preparing to initiate lysosomal degradation. By fusing with lipids at this stage in endosomal
processing, DOPE can facilitate release of the DNA before degradation begins [19]. Additionally,
cationic lipids can enhance performance of viral vectors as well. Incubation with cationic
liposomes increases the gene expression efficiency, reduces the associated immunogenicity,
and/or modifies the tropism of certain viral vectors [20–22].

1.5 Cationic Glucocorticoids for Improving Gene Therapies of CF
One particular category of cationic lipid has particular promise for enhancing gene
therapies of CF, namely lipids that are spermine-based cationic glucocorticoids. Two such
compounds, dexamethasone spermine (DS) and disubstituted dexamethasone spermine (D2S)
(Figure 1.3), were previously developed by this lab and shown to have both anti-inflammatory
and antimicrobial characteristics [23,24]. This dual functionality is particularly suited for
applications in CF, a disease characterized by on-going inflammation and chronic infections with
opportunistic bacteria. Dual acting cationic lipids, like DS, D2S, and similarly structured cationic
glucocorticoids, could be used to facilitate better gene transfer of gene therapy vectors while also
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treating the infection and hyperinflammatory environment so commonly encountered in CF
patients.

Figure 1.3: Chemical structures of DS and D2S

1.5 Current Research Goals
DS and D2S showed promising pharmacological activity in vitro, but the in vivo efficacy
of these compounds had not been verified at the start of this work. While seemingly simple in
theory to execute, this task was difficult to accomplish due to the lack of a relevant and
convenient animal model in which to test potential therapeutics for CF. Mice that have been
engineered to lack the CFTR gene do not show the airway disease typically seen in CF humans
[25]. Furthermore, P. aeruginosa, the bacterium responsible for most chronic infections in CF
patients, is not a naturally infectious pathogen of murine animals. If the bacteria are not first
embedded in an artificial biofilm (i.e. embedded in beads composed of agar, agarose, or seaweed
alginate) before administration to the animal, a lasting infection is unachievable [26].
Administration of free bacteria results in either rapid clearance of the organism or acute sepsis
and death [27].
1.5.1 Specific Aim 1: Mouse Models of Infection for In Vivo Evaluation of Airway Gene Transfer
Consequently, the first objective of this work was to establish non-invasive and
reproducible in vivo models of airway infection to test potential therapies relevant for CF airway
6

disease. Separately, the models presented here incorporate different aspects of clinical
presentations of CF airway disease. Methods for one model establishes a chronic airway infection
with a natural murine pathogen, while methods for the other two models establish infections that
are more acute in nature but utilize P. aeruginosa in a physiological environment relevant for CF.
1.5.2 Specific Aim 2: Structure-activity Relationships of Novel Cationic Glucocorticoids
The second objective of this work was to investigate structure-activity relationships of
similarly structured cationic glucocorticoids. DS and D2S, while potent in vitro, may not be the
most ideal choices for practical applications in treating CF airway disease. Preliminary studies on
the effects of D2S in rat models of arthritis demonstrated significant systemic activity of the lipid
in the body [28]. While local anti-inflammatory (i.e. immunosuppressive) activity is a desirable
trait for potential CF treatments, compounds with strong systemic activity could be ultimately
lethal during situations involving active infections. Thus, ideal therapeutic candidates are
compounds with potent local effects but limited systemic consequences. In this work, six new
cationic glucocorticoids were synthesized and characterized to further understanding of how this
family of compounds can be modified accordingly to achieve such desired characteristics.
1.5.3 Specific Aim 3: In Vivo Evaluation of Coordinated Gene Therapies with Anti-inflammatory
and Antimicrobial Cationic Glucocorticoids during Active Airway Infections
Ultimately, the goal of this work is to coordinate gene therapies with these dual
functioning cationic glucocorticoids and validate these methods as treatments for CF airway
disease. The final objective of this work was to test these coordinated therapies in the animal
models established as part of Specific Aim 1. Two of the novel cationic glucocorticoids
developed in Specific Aim 2 showed particularly promising in vitro potency and were used to
establish proof-of-concept efficacy in vivo.
7

2.0 In vivo evaluation of adeno-associated virus gene transfer in
airways of mice with acute or chronic respiratory infection
2.1 Abstract
While gene therapy development for CF often involves viral-based vectors, little is
known about gene transfer in the context of an infected airway. In this study, three mouse models
were established to evaluate adeno-associated virus (AAV) gene transfer in such an environment.
Bordetella bronchiseptica RB50 was used in a chronic, non-lethal respiratory infection in
C57BL/6 mice. An inoculum of ~105 CFU allowed B.bronchiseptica RB50 to persist in the upper
and lower respiratory tracts for at least 21 days. In this infection model administration of an AAV
vector on day 2 resulted in an approximately three-fold reduction of reporter gene expression
compared to that observed in uninfected controls. Postponement of AAV administration to day 14
resulted in an even greater (eight-fold) reduction of reporter gene expression, when compared to
uninfected controls. In another infection model Pseudomonas aeruginosa PAO1 was used to
infect surfactant protein D (SP-D) or surfactant protein A (SP-A) knockout (KO) mice. With an
inoculum of ~105 CFU, infection persisted for two days in the nasal cavity of either mouse model.
Reporter gene expression was approximately ~2.5 fold lower compared to uninfected mice. In the
SP-D KO model, postponement of AAV administration to day 9 post-infection resulted in only a
2-fold reduction in reporter gene expression, when compared to expression seen in uninfected
controls. These results confirm that respiratory infections, both on-going and recently resolved,
decrease the efficacy of AAV-mediated gene transfer.
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2.2 Introduction
Deterioration of the lung in CF patients is due to a cycle of infection by opportunistic
pathogens and neutrophilic inflammation [29]. By the age of 17, nearly 70% of CF patients have
P. aeruginosa in their sputum at levels of 106-108 CFU/gr sputum [30], and approximately 80%
of adult CF patients are chronically infected with P. aeruginosa that cannot be eliminated by
antibiotic therapy [7]. In a Phase II gene therapy trial with AAV-CFTR, nearly 70% of CF
patients receiving the AAV2 vector were P. aeruginosa colonized [31]. The presence of infection
was an endpoint of measurement in the trial and was not a basis for exclusion from the trial.
Separately, a Phase IIB trial with AAV2-CFTR that included three doses of 1013 particles
administered 30 days apart failed to demonstrate efficacy [32]. In this clinical trial of 102 CF
subjects, the number of days of antibiotic use was considered a marker for trial monitoring.
Infection in CF airways is expected during the progress of the gene therapy regimen, and about
15% of CF subjects were on antibiotics while they received aerosolized AAV2 for this study. In a
clinical trial of interferon gamma-1b with 66 CF patients, sputum bacterial density was 7.1 Log10
CFU/gr with 80 to 90% of enrolled subjects having P. aeruginosa infection [33]. The sickest CF
patients have chronic lung infection but the presence of P. aeruginosa in sputum has not been a
criterion for exclusion in airway-directed gene therapy clinical trials. The failure of CF AAV
gene therapy trials may be due in part to the difficulty of gene delivery to lungs that sustain and
harbor a chronic disease state due to infection. Little research, however, has been done to
investigate the effects of microbial infection on airway gene transfer.
The paucity of research in this area may be related to the lack of a relevant animal model
necessary to study such effects. Current methods are laborious and introduce issues of mechanical
and physical damage that are not naturally seen with clinical presentations of CF. This study
presents three alternatives for studying gene transfer in an infected airway that are reproducible
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and non-invasive. The first involves a natural murine pathogen, Bordetella bronchiseptica (Bb)
RB50, to establish a chronic infection in C57BL/6 mice. Bb infects a number of members of the
mammalian family, and in rodents, rabbits, cats, dogs, and pigs, it typically establishes an
asymptomatic infection in the nasal cavity that persists indefinitely [34,35]. In the lower
respiratory tract, the infection is enduring, but transient, with the bacterial load reducing to almost
baseline within 45 days [35]. The second and third scenarios utilize P. aeruginosa PAO1 to
establish an acute infection in surfactant protein D (SP-D) and surfactant protein A (SP-A)
knockout mice, respectively. SP-D and SP-A are pulmonary collectins that are important in
innate immunity against various bacterial and viral pathogens [36]. Decreased or lack of SP-D
and SP-A has been implicated in the pathogenesis of CF airway disease [37]. When knockout
mice were engineered to lack either SP-D or SP-A, they were found to have decreased ability to
effectively clear P. aeruginosa [38]. The resulting infection was still transient lasting only a few
days, but the resulting inflammatory response was exaggerated when compared to WT mice. As
hyperinflammatory responses are also typical of CF patients, the SP-D and SP-A KO mice
emulate key inflammatory aspects of the disease when compared to WT mice.
In this report, we employed these mouse models to study adeno-associated virus (AAV)mediated gene transfer in infected airways. Figure 2.1 depicts the experimental design used. The
presence of an on-going or even recently resolved infection decreased AAV-mediated gene
transfer efficiency in the airway, validating the use of these models to optimize gene transfer for
relevant airway diseases like CF.
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Figure 2.1: A schematic of experimental design.
Mice are i.n. infected with freshly cultured bacteria on day 0. On day 2, 9, or 14, an AAV9 vector containing a ffluc
reporter gene is introduced to the recently infected airway via intranasal instillation. Three to four randomly selected
mice are also taken on the day of AAV administration for evaluation of bacterial load and characterization of immune
response at the time of vector administration (n=3 for uninfected controls, n=4 for infected groups). Approximately
every week thereafter, the remaining mice are dosed with luciferin and subjected to live imaging to evaluate ffluc
expression. Abbreviations: AAV, adeno-associated virus; IN, intranasal; ffluc, firefly luciferase; NLF, nasal lavage
fluid; BALF, bronchoalveolar lavage fluid.

2.3 Materials and Methods
2.3.1 Bacterial Strains and Growth Conditions
B. bordetella strain RB50 was a kind gift from Dr. Yasuhiko Irie, University of
Washington, Seattle, WA. Bb was cultured in Stainer-Scholte (SS) broth or on Bendet Gengou
(BG) blood agar (BD Diagnostic Systems, Sparks, MD) at 37°C. P. aeruginosa PAO1 was a kind
gift from Dr. Robert Bucki, University of Pennsylvania, Philadelphia, PA. The bacterium was
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cultured at 37°C in Miller’s Lysogeny Broth (LB) (Mediatech, Herndon, VA) or on Pseudosel™
Agar (cetrimide agar) from BD Diagnostic Systems.
2.3.2 AAV Preparation
The AAV9 vectors flanked with AAV2 inverted terminal repeats (ITRs) contained a
firefly luciferase (ffluc) reporter gene fused to a nucleus localization sequence at the N-terminus
under the transcriptional control of the cytomegalovirus (CMV)-enhanced chicken-β-actin
promoter. Vectors were produced by the Penn Vector core as previously described [39].
2.3.3 Mice
C57BL/6 male mice were purchased from Charles River Laboratories (Wilmington, MA),
while SP-D and SP-A knockout mice [40] were maintained in-house at the University of
Pennsylvania. Mice were age-matched and used between 7 and 14 weeks of age. For all
experiments, a group size of at least 3 mice was used for each experimental cohort. All animals
were maintained at the Animal Facility of the Translation Research Laboratories at the University
of Pennsylvania under protocols reviewed and approved by the University of Pennsylvania’s
Institutional Animal Care and Use Committee. Prior to all intranasal administrations, mice were
anesthetized by an intraperitoneal injection of ketamine/xylazine (70/7 mg/kg) and were
subsequently suspended from their dorsal incisors (hind quarters supported) for dosing.
2.3.4 Preparation of Inoculum
Bacteria were grown overnight in their appropriate liquid media at 37°C with shaking at
250 rpm. Approximately 16-18 hours later, the bacteria were diluted into fresh broth to an optical
density (λ=600nm) reading of 0.1 and were allowed to grow until mid-logarithmic phase (optical
density at λ=600nm of ~0.5 for Bb RB50 and ~0.4 for P. aeruginosa). At that point, the bacteria
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were harvested and washed once in phosphate-buffered saline (PBS) before being diluted into
fresh PBS at the desired concentration (controlled by evaluation of optical density at 600 nm).
2.3.5 Mouse Infection Model for Evaluation of Airway Transduction
Before challenge, mice were anesthetized intraperitoneally and suspended from their
dorsal incisors, as described earlier. Mice were then intranasally (i.n.) challenged with a 30-µL
bolus (delivered as two 15 µL aliquots, one into each nostril) of Bb RB50 or P. aeruginosa PAO1
to achieve approximately 105 CFU/mouse. At specified time points later (i.e. 2, 9, or 14 days after
infection), mice were i.n. administered 5 × 1010 genome copies (GC) of AAV vector in 20-µL (10
µL into each nostril).
To evaluate ffluc expression, mice (~20 grams) were anesthetized and suspended before
20 µL of D-luciferin (15 mg/mL) was i.n. administered as two 10 µL aliquots, one into each
nostril. After 5 minutes, mice were imaged for 60 seconds with the IVIS Xenogen imaging
system. Quantification of signal was calculated with the Living Image 2.5.1 software.
2.3.6 Evaluation of Bacterial Load
To determine bacterial load, three samples were taken from each randomly selected
mouse: (a) lungs, (b) bronchoalveolar lavage fluid (BALF), and (c) nasal lavage fluid (NLF).
Before the lungs were harvested, BALF was collected by instilling 500 µL of sterile PBS through
a cannula into the trachea. Fluid was collected and re-instilled into the lungs for a total of three
times before being collected into a 1.5-mL tube. The lungs (~110-150mg per lung) were then
excised. One lung was inflated with a 1:1 mixture of Tissue Tek® OCT and PBS, embedded in
OCT in a storage cassette and flash frozen with cooled 2-methylbutane. Frozen lungs were kept at
-80°C until further histological processing. The other lung was homogenized in 1.5 mL of sterile
PBS for evaluation of bacterial load. For the NLF samples, mice were decapitated and a cannula
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attached to a 1-mL syringe containing 300 µL of sterile PBS was placed into the tracheal
remnant. PBS was then flushed through the nasal passages and collected through the nares into a
1.5-mL tube. This recovered fluid was used to flush the nasal cavity another two times, for a total
of three flushes. All samples were kept on ice until further processing.
To determine the CFU counts in each sample, solutions were diluted 10-, 100-, and 1000fold. Ten-microliter aliquots of each dilution were spotted in duplicate on the appropriate solid
selection agar for each bacterial strain (BG blood agar for Bb and Pseudosel™ agar for P.
aeruginosa). Plates were incubated at 37°C for 48 hours for Bb RB50 and 16 hours for P.
aeruginosa. The number of colonies at each dilution was then counted, and the concentration of
CFU of each sample was back calculated from the dilution factor.
2.3.6 BALF Cell Analysis
Cytospin slides were prepared using 50 µL of freshly isolated BALF diluted into 100 µL
of fresh PBS. After centrifugation (Shandon Cytospin 3, Thermo Fisher Scientific Inc., Waltham,
MA) for 5 minutes at 1,000 rpm, cells were allowed to air dry for 10 minutes. Cells were then
fixed with 10% neutral buffered formalin, washed in PBS, stained with Nuclear Fast Red (Sigma
Aldrich, St. Louis, MO), dehydrated with a series of ethanols, and cleared with xylene according
to standard protocols. Cells were studied and characterized using light microscopy (IX81;
Olympus America Inc., Center Valley, PA).
2.3.7 Lung Immunohistochemistry
Immunofluorescence staining was performed on frozen lung sections. Sections were
fixed in acetone at -20ºC for 7 min, air dried, blocked in 1% donkey serum in PBS for 20 min,
and incubated with primary rat antibodies diluted in blocking buffer against CD8 (clone 53-6.7,
BD Biosciences; 1:20), CD4 (clone RM4-5, BD Biosciences; 1:20), and Mac-2 (clone M3/38,
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Cedarlane; 1:200) for 45 min. After washing in PBS sections were stained with secondary donkey
antibodies labeled with FITC or TRITC (Jackson Immunoresearch Laboratories) for 30 min,
washed in PBS, and mounted in Vectashield containing DAPI (Vector Laboratories). For
detection of neutrophils, cryosections were fixed in 4% paraformaldehyde in PBS for 10 min.
Sections were then permeabilized and blocked in 0.2% Triton containing 1% donkey serum for
30 min and stained with a rabbit antibody against myeloperoxidase (Abcam) followed by
secondary antibodies and washing steps as described above.
2.3.8 BALF Cytokine Analysis
A multiplex bead assay based on the Luminex technology was used to measure
cytokine/chemokine levels in BALF samples that were collected from mice as described earlier.
A 25-panel multi-analyte cytokine/chemokine kit (Millipore, MA) was used according to the
manufacturer’s instructions. Briefly, 25 μL of samples were incubated overnight at 4°C with
capture beads against G-CSF, GM-CSF, IFN-γ, TNF-α, RANTES, IL-1α, IL-1β, IL-2, IL-4, IL-5,
IL-6, IL-7, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17, IP-10, KC, MCP-1, MIP-1α,
MIP-1β, and MIP-2 on a rocking platform. The following day beads were washed using a hand
held magnetic block (Millipore, MA) and stained with biotin antibodies at room temperature for
one hour. The beads were further stained for 30 min using streptavidin detection antibodies
before a series of final washes. Beads were read on a Luminex 200 instrument (Luminex, TX)
and levels determined by regressing against a 7-point standard curve (Bioplex Manager, Biorad).
2.3.9 Statistical Analysis
Statistical analysis was performed using Microsoft Office Excel 2007 (Microsoft,
Redmond, WA). The Student’s t-Test was used to determine significance of differences between
two groups.
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2.4 Results
To evaluate the effects of a chronic bacterial infection on gene transfer in the airway,
C57BL/6 mice were i.n. challenged with approximately 105 CFU of Bb RB50 or sterile PBS.
Mice were tested for evidence of infection through day 21 post-infection, and in all RB50infected mice, bacteria were detected at significant levels (104-107 CFU) in both the nasal cavity
and lung throughout the duration of the study (Figure 2.2A). All samples from mice receiving
only sterile PBS showed no evidence of RB50 at all time points tested (data not shown). On day 2
or day 14 of infection, mice were given an intranasal dose of AAV9.ffluc. One week after AAV
administration, mice were subjected to live whole animal luminescent imaging. At both time
points, the luminescent signal in the nasal cavity of the infected mice was significantly lower
(P<0.01, Student’s t-Test) than that observed in the nasal cavity of the uninfected mice (Figure
2.2, B and C). It is worthwhile to note that the loss in expression was greater (eightfold, Figure
2.2C) when AAV administration was delayed to day 14 of infection. The significant difference in
ffluc expression in the nasal cavity between uninfected mice and infected mice receiving AAV on
day 14 was sustained for 50 days after AAV delivery (Figure 2.3).
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Figure 2.2: Effects of a sustained RB50 airway infection on AAV9-mediated transduction in C57BL/6 mice.
(A) RB50 colonization of C57BL/6 mouse airway. Approximately 10 5 CFU of bacteria were delivered i.n. in 30 µL.
Bacterial colonization was analyzed through harvest of lungs, BALF, and NLF from three to four randomly selected
mice at specified time points over the course of 21 days. The plots show means ± standard deviations for n=4-11 mice
tested at each time point in four different experiments. Samples taken from uninfected mice were clear of RB50 at all
time points. Dashed line denotes detection limit. Abbreviations: BALF, bronchoalveolar lavage fluid; NLF, nasal
lavage fluid. (B and C) AAV9-mediated transduction in wild-type C57BL/6 mice recently infected with RB50. Two
or fourteen days after receiving intranasal inoculations of either sterile PBS or ca. 105 CFU of B. bronchiseptica, mice
were i.n. dosed with AAV9.ffluc. Mice were later assessed for gene expression one week later: (B) mice that received
AAV on day 2 of infection and (C) mice that received AAV on day 14 of infection. Plots show quantification of
luminescence from mouse nasal cavity. Results are presented as means, and error bars represent the standard deviation
for the six mice imaged at each time point. Significantly lower signal was observed from the nasal cavities of infected
mice (**P < 0.01, Student’s t-Test, n=6).
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Figure 2.3: Long-term AAV9 gene expression in nasal cavities of C57BL/6 mice previously infected with RB50.
Animals were transduced with AAV9.ffluc on day 14 of a Bb infection and imaged for ffluc expression every week
until day 86 post-AAV administration. Bb-infected mice show significantly lower nasal cavity luminescence than that
observed from uninfected controls through day 50 (**P<0.01, *P<0.05, Student’s t-test, n=6 at day 7, n=3 for all other
time points).
PBS, AAV9,
Bb, AAV9.

To determine whether a transient acute infection would have a similar effect, P.
aeruginosa PAO1 was used to infect SP-D knockout mice. Mice were i.n. challenged with
approximately 105 CFU of PAO1 and control mice given sterile PBS. On day 2 or day 9 postinfection, a representative sampling of mice (uninfected n=3, infected n=4) was taken to
determine the status of the infection in the lungs and nose at the time of AAV administration
(Figure 2.4, A and B). Samples from uninfected mice showed no evidence of PAO1 at both time
points tested (data not shown). On day 2, PAO1 was only found in the nasal cavity at relatively
low levels (~80 CFU). Lung and BALF samples isolated from the lower respiratory tract showed
no evidence of infection. By day 9, the majority of mice had cleared the bacteria from their
airways. However, despite the limited presence of bacteria in the nasal cavity, ffluc expression
was still significantly lower (P<0.01, Student’s t-Test) in the noses of infected mice in both cases
(Figure 2.4, D and E). Consistent observations were seen at subsequent time points through to day
14 post-transduction (Figure 2.5,A-B).
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Figure 2.4: Effects of a transient P. aeruginosa PAO1 airway infection on AAV9-mediated transduction in SP-D
or SP-A KO mice.
(Top, A-C) PAO1 colonization of SP-D or SP-A KO mouse airway. Approximately 105 CFU of bacteria were delivered
i.n. in 30 µL. Bacterial colonization was analyzed through harvest of lungs, BALF, and NLF from three or four
randomly selected mice at specified time points: (A) SP-D KO mice at day 2 post-infection, (B) in SP-D KO mice at
day 9 post-infection, and (C) in SP-A KO mice at day 2 after infection. Plots show means ± standard deviations for
n=5-7 mice tested at each time point in three different experiments for SP-D KO mice and n=3 mice from a single
experiment for SP-A KO mice. Samples taken concurrently from uninfected mice were clear of PAO1 at all time points
tested. Abbreviations: BALF, bronchoalveolar lavage fluid; NLF, nasal lavage fluid. (Bottom, D-F) AAV9-mediated
transduction in SP-D or SP-A KO mice recently infected with PAO1. Two or nine days after being challenged with
sterile PBS or approximately 105 CFU of P. aeruginosa PAO1, mice were i.n. dosed with AAV9.ffluc. One week later,
mice were imaged for gene expression: (D) SP-D KO mice that received AAV on day 2 of infection, (E) SP-D KO
mice that received AAV on day 9 of infection, and (F) SP-A KO mice that received AAV on day 2 of infection. Plots
show quantification of luminescence from mouse nasal cavity. Results are presented as means, and error bars represent
the standard deviation for the mice imaged at each time point. Significantly lower signal was observed from the nasal
cavities of infected mice (**P < 0.01, *P < 0.05, Student’s t-Test, uninfected n=6, infected SP-D KO mice receiving
AAV on Day 2 n=11, infected mice SP-D KO receiving AAV on Day 9 n=8, n=7 for both SP-A KO mice groups).

To determine whether infection would have similar effects on gene expression in mice
lacking SP-A, the SP-A KO mice were i.n. challenged with ~105 CFU of PAO1 or sterile PBS.
On day 2 post-infection, mice (uninfected n=3, infected n=4) were peeled to mice determine the
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status of infection in the SP-A nasal and lung airways at the time of AAV administration (Figure
2.4C). As observed in the SP-D KO mice, bacteria were only found in the nasal cavity at
relatively low levels (~80 CFU) on day 2 post-infection, and samples from uninfected mice
showed no evidence of PAO1 (data not shown). Additionally, similar trends on reporter gene
expression were also observed; ffluc expression was significantly lower (P<0.05, Student’s t-Test)
in the nasal cavity of infected mice (Figure 2.4F). Consistent observations were seen at
subsequent time points through day 21 post-transduction (Figure 2.5C).

Figure 2.5: Long-term AAV9 gene expression in nasal cavities of SP-D or SP-A KO mice previously infected
with PAO1.
(A) SP-D KO mice transduced on day 2 of infection. (B) SP-D KO mice transduced on day 9 of infection. (C) SP-A
KO mice transduced on day 2 of infection. Mice were imaged every week until the specified day post-AAV
administration. PAO1-infected mice show significantly lower nasal cavity luminescence than that observed from
uninfected mice through the first two time points in each experiment (**P<0.01, *P<0.05, Student’s t-Test, for (A):
Day 7 uninfected n=6, Day 7 infected n=10, for all other time points uninfected n =3 and infected =6; for (B): Day 7
uninfected n=6, Day 7 infected n=8, for all other time points uninfected n =3 and infected=4; for (C): Day 7 uninfected
n=7, Day 7 infected n=7, for all other time points: uninfected n=3 and infected n=4 ).
PBS, AAV9,
PAO1,
AAV9.

The immune response at the time of AAV administration was then characterized to
provide insights into the observed mechanisms. Cytology on fresh BALF samples indicated that
actively infected mice were characterized by substantial neutrophil infiltration on day 2 of
infection (Figures 2.6R, 2.7R, 2.8J). Samples from uninfected mice only showed evidence of
alveolar macrophages (Figures 2.6Q, 2.7Q, 2.8I). Interestingly, uninfected SP-D KO mice had a
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small number of neutrophils in their BALF samples in addition to macrophages that were
characterized by a foamy and/or multi-nucleated appearance (Figure 2.7Q). By day 9 post-PAO1
infection, many of the neutrophils had band, rather than segmented, nuclei (Figure 2.7T),
indicative of a shift towards immature precursors.
Histology on frozen lung sections showed similar trends (Figures 2.6-2.8). Day 2 of
infection was characterized by significant neutrophil and macrophage infiltration for the Bb
chronic infection and the PAO1 acute infection in the SP-A KO model (Figures 2.6 and 2.8, E-H).
Day 2 of infection was also characterized by an elevated CD8 T cell population in the SP-A KO /
PAO1 model (Figure 2.8G). Interestingly, in the SP-D KO / PAO1 acute infection model,
neutrophils and macrophages were present in the lungs of uninfected mice (Figure 2.7, A and B).
We also observed small numbers of CD8 T cells in the uninfected lung and these increased
slightly with infection. By day 9 post-infection with PAO1, lung samples from the SP-D KO mice
showed little to no differences between uninfected and infected groups for all cell types detected
(Figure 2.7N). Day 14 of Bb infection in C57BL/6 mice, on the other hand, was characterized by
elevated neutrophil and macrophage populations (Figure 2.6, M and N). Additionally, day 14
samples from infected lungs also showed a larger presence of CD4 T cells but not CD8 T cells
(Figure 2.6, O and P).
Analysis of cytokine/chemokine levels in BALF samples isolated from a representative
sampling of mice (typically uninfected n=3, infected n=4) at the time of AAV administration
demonstrated the most notable differences on day 2 of infection for all infection models (Figure
2.9). Of the 25 analytes measured, nine of them (GM-CSF, IL-2, IL-4, IL-5, IL-7, IL-9, IL-12p40,
IL-13 and IL-15) showed no differences between groups in any of the infection models used in
this study (data not shown). The remaining 16 (G-CSF, IFN-γ, IL-1α, IL-1β, IL-6, IL-10, IL12p70, IL-17, IP-10, KC, MCP-1, MIP-1γ, MIP-1β, MIP-2, TNF-α, and RANTES) displayed
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substantial differences between uninfected and infected groups on day 2 post-infection in at least
one of the infection models tested (Figure 2.9). Determination of statistical significance for
differences observed in the SP-A KO / PAO1 model was limited by the number of samples
available for analysis (n=2 for each group). At the later time points tested, i.e. at day 14 after Bb
infection and at day 9 after PAO1 infection, many of the elevated analytes (i.e., G-CSF, IFN-γ,
IL-1β, IL-6, IL-10, IL-12p70, IP-10, MCP-1, and MIP-1γ) returned to baseline. The remaining
analytes, IL-1α, IL-17, KC, MIP-1β, MIP-2, TNF-α, and RANTES, were still elevated in samples
obtained from Bb-infected mice. In the SP-D KO / PAO1 model, all cytokines and chemokines
levels had returned to baseline by day 9 post-infection.
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Figure 2.6: Characterization of immune response at time of AAV administration in Bb chronic infection model.
(A-P), Lung histology of C57BL/6 mice transduced at specified time points during Bb airway infection. Lungs were
harvested on the day of AAV administration and sectioned and stained with antibodies against antigens for the
specified cell type. Representative images are shown here: sections from (A-D) uninfected mice on day 2, (E-H)
infected mice on day 2, (I-L) uninfected mice on day 14, and (M-P) infected mice on day 14. Notable neutrophil and
macrophage infiltration was observed in samples from infected lungs. Day 9 showed an elevated CD4 T cell population
as well. Arrows indicate evidence of elevated cell populations. Magnification, x 20. (Q-T) Cytospin preparations of
cells recovered from fresh BALF samples taken on day of AAV administration: (Q,S) samples taken from uninfected
mice on day 2 and day 14, respectively, (R,T) samples taken from infected mice on day 2 and day 14, respectively.
Representative macrophages (Ma) and neutrophils (Ne) are indicated in the figure. Samples from uninfected mice
showed only macrophages, while samples from infected mice showed a prominent neutrophil presence in addition to
the macrophage cell population at both time points.
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Figure 2.7: Characterization of immune response at time of AAV administration in SP-D KO / PAO1 acute
infection model.
(A-P), Lung histology of SP-D KO mice transduced at specified time points during PAO1 airway infection. Lungs were
harvested on the day of AAV administration and sectioned and stained with antibodies against antigens for the
specified cell type. Representative images are shown here: sections from (A-D) uninfected mice on day 2, (E-H)
infected mice on day 2, (I-L) uninfected mice on day 9, and (M-P) infected mice on day 9. Day 2 samples from
uninfected mice displayed evidence of neutrophils, macrophages, and CD8 T cells. Infected samples at this time point
showed slightly elevated levels of the same cell types, as indicated by the arrows. By day 9, only macrophages remain
slightly elevated. Magnification, x 20. (Q-T) Cytospin preparations of cells recovered from fresh BALF samples taken
on day of AAV administration: (Q,S) samples taken from uninfected mice on day 2 and day 9, respectively, (R,T)
samples taken from infected mice on day 2 and day 9, respectively. Representative macrophages (Ma), neutrophils
(Ne), and band neutrophils (band Ne) are indicated in the figure. Day 2 samples from uninfected mice showed
macrophages and a small neutrophilic presence. Infected samples at this same time point displayed a much larger
neutrophils population. By day 9, both macrophages and neutrophils were still seen. However, neutrophils on day 9 had
band (instead of segmented) nuclei, indicative a shift towards immature precursors.
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Figure 2.8: Characterization of immune response at time of AAV administration in SP-A KO / PAO1 acute
infection model.
(A-H), Lung histology of SP-A KO mice transduced on day 2 during PAO1 airway infection. Lungs were harvested on
the day of AAV administration and sectioned and stained with antibodies against antigens for the specified cell type.
Representative images are shown here: sections from (A-D) uninfected mice and (E-H) infected mice. On day 2,
elevated levels of neutrophils, macrophages, and CD8 T cells were evident in samples from infected lungs (see arrows).
Magnification, x 20. (I-J) Cytospin preparations of cells recovered from fresh BALF samples taken on day of AAV
administration: (I) samples taken from uninfected mice and (J) samples taken from infected mice. Representative
macrophages (Ma) and neutrophils (Ne) are indicated in the figure. Samples from uninfected mice showed only
macrophages, while infected samples showed obvious neutrophil infiltration in addition to the macrophage cell
population.
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Figure 2.9: BALF cytokine/chemokine levels at time of AAV administration.
Cytokine/chemokine levels were determined using a Milliplex 25-plex premixed magnetic mouse cytokine/chemokine
array and Luminex bead reader according to the manufacturer’s instructions. Single asterisk (*) indicates samples that
exceeded the upper limit of detection of the assay, approximately 10,000 pg/mL. Results are presented as means, and
error bars represent the standard deviation (··P<0.01, ·P<0.05, Student’s t-Test, uninfected n=2-5, infected n=3-7 for all
groups except SP-A KO infected mice where n=2 for both uninfected and infected mice).
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2.5 Discussion
CF airway disease remains an ideal candidate for treatment by gene therapy, despite its
limited success seen so far. Individuals with CF are characterized by chronic respiratory
infections that are primarily responsible for the high morbidity and early mortality rates
associated with the disease. However, limited research has been done to determine the effects of
active airway infections on pulmonary gene transfer. The lack of research on this topic is not
surprising as no convenient animal model exists to study such effects. Three different mouse
models were established in this study to remedy this issue. The first involved creating a chronic
infection in C57BL/6 mice with a natural murine pathogen, B. bronchiseptica RB50. The second
and third models utilized PAO1 to establish an acute, but persistent, infection in SP-D and,
separately, SP-A KO mice, respectively.
When an AAV vector was administered to the airways of infected mice on day 2 postinfection, transduction efficiency was similarly reduced in all mouse models, despite remarkable
differences in the duration and intensity of all infection models. The approximate 3-fold reduction
in gene expression was seen regardless of several additional factors, including the bacterium
used, the strain of mouse used, or the bacterial load at the time of AAV administration. This
suggests that immune response at the time of vector administration was the main cause for the
observed reduction in gene transfer efficiency.
Characterization of these immune responses at day 2 of infection showed that the
responses in each infection model were generally similar to each other. Analyses showed that day
2 inflammatory responses were dominated by macrophage and neutrophil infiltration, the latter of
which is characteristic of the infected CF lung [29]. However, in the SP-D KO / PAO1 acute
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infection model, elevated levels of macrophages and neutrophils were present even in uninfected
lung samples, suggesting that their presence alone is insufficient to reduce gene transfer.
While immune responses at day 2 were generally similar between all infection models
studied, one striking difference observed was between the chronic and transient acute infection
models. In the SP-D and SP-A KO / PAO1 infection models, CD8 T cell activation/recruitment
was observed in the infected lungs. In the lungs of Bb-infected mice, the numbers of CD8 T cells
were not elevated compared to uninfected mice. Despite this apparent difference, we observed a
similar level of reduction in gene expression in all three infection models, suggesting that CD8 T
cells are not directly involved in the reduction of gene transfer.
When AAV administration was delayed to a later time point post-infection, different
effects on AAV-mediated gene expression were seen between the Bb chronic infection and the
SP-D KO / PAO1 acute infection models. In the Bb chronic infection model, postponement of
AAV administration to day 14 post-infection resulted in a significant (8-fold, P<0.01, Student’s tTest) reduction in gene expression when compared to the expression seen in uninfected controls.
In the SP-D KO / PAO1 acute infection model, however, delay of AAV administration to day 9
post-infection resulted in a ~2-fold reduction. The notable differences observed in the immune
response at these time points include: (1) elevated levels of macrophages, segmented neutrophils,
and CD4 T cells in Bb-infected mice but not in PAO1-infected mice and (2) elevated levels of IL1α, IL-17, KC, MIP-1β, MIP-2, TNF-α, and RANTES in Bb-infected mice but not PAO1-infected
mice. While PAO1-infected SP-D mice did display elevated levels of neutrophils in their BALF
samples, many of these cells showed a band, rather than a segmented, nucleus, indicative of
immature neutrophilic precursors. Taken together, these results indicate that activated, mature
neutrophils and CD4 T cells may be responsible for causing significant reduction in gene
expression observed in the Bb-infected mice. In particular, the presence of the CD4 T cells may
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be playing the more significant role, as that cell type was not present at the earlier AAV
administration time point (day 2 post-infection), which reduced gene expression by only ~3-fold.
Additionally, it is worthwhile to note that one of the elevated cytokines on day 14 of the
chronic infection, IL-17, is produced by CD4 T cells and has been implicated in the stimulation of
airway mucin gene expression [41]. This could suggest the development of an enhanced mucus
barrier by day 14 of the chronic infection. Such a phenomenon could explain the significant loss
in gene transfer efficiency at this later time point for AAV administration. The enhanced mucus
layer would prevent transduction by hindering normal transport of vector to the target cells.
In several studies, AAV vector administrations targeting liver have proven to be safe and
rarely elicit an immune response, even when challenged with an adenovirus expressing a similar
transgene [42,43]. However, co-administration of TLR ligands, including CpG-containing ODNs,
along with antigen-specific T cells or adenoviruses led to loss of liver transgene expression
[42,43]. It is likely that in our models, the inflammatory microenvironment and cytokine release
profile following bacterial infections may have resulted in the breaking of immune tolerance to
AAV particles and/or their gene products. Hence, the bacterial presence in our infection models
likely serves as a form of adjuvant, triggering sufficient immunity to the AAV vector and/or to
the ffluc product to result in a diminished expression or visualization thereof.
In each of our models, free bacteria were administered to the nares of healthy mice to
facilitate a prolonged infection of the respiratory tract. The administration of free bacteria
contrasts with the established practice of artificially embedding bacteria in agar beads before
depositing them into the airway through a tracheal incision. The methods presented here are thus
simpler and less invasive. Additionally, our methods do not limit the infection to the conducting
airways, which is not the case with methods involving embedded beads. Due to their size, the
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beads create a mechanical block to the bronchi, resulting not only in limited bacterial access to
the respiratory airways but also in increased morbidity, unwanted lung damage, and potentially
even collapse or closure of the lung [44].
To the best of our knowledge, this the first study to examine the effects of an active, naturally
occurring respiratory infection on AAV airway gene transfer. Our findings clearly show that the
efficiency of AAV-mediated gene transfer in the airway is negatively impacted by the presence of
an on-going or recently resolved bacterial infection. These results underscore the importance of
considering such circumstances when developing potential genetic treatments for relevant
diseases, like CF and potentially other airway diseases such as asthma. The methods validated
here provide simple and minimally invasive techniques that will allow this type of infected
environment to be more easily accounted for.
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3.0 Synthesis and structure-activity relationships of novel cationic lipids
with anti-inflammatory and antimicrobial activities
3.1 Abstract
Certain membrane-active cationic steroids are known to also possess both antiinflammatory and antimicrobial properties. This combined functionality is particularly relevant
for potential therapies of infections associated with elevated tissue damage, e.g. cystic fibrosis
airway disease, a condition characterized by chronic bacterial infections and ongoing
inflammation. In this study, six novel cationic glucocorticoids were synthesized using
beclomethasone, budesonide, and flumethasone. Products were either monosubstituted or
disubstituted, containing one or two steroidal groups, respectively. In vitro evaluation of
biological activities demonstrated dual anti-inflammatory and antimicrobial properties with
limited cytotoxicity for all synthesized compounds. Budesonide-derived compounds showed the
highest degree of both glucocorticoid and antimicrobial properties within their respective monoand disubstituted categories. Structure-activity analyses revealed that activity was generally
related to the potency of the parent glucocorticoid. Taken together, these data indicate that these
types of dual acting cationic lipids can be synthesized with the appropriate starting steroid to
tailor activities as desired.
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3.2 Introduction
Pathophysiological symptoms of CF airway disease are cyclic in intensity, with the more
intense periods termed “exacerbations.” Such exacerbations are associated with high bacterial
(usually, P. aeruginosa) concentrations in the airway sputum, and aggressive antibiotic treatment
is typically required to improve lung function [45,46]. However, while early P. aeruginosa
infections are susceptible to common anti-pseudomonal antibiotics (e.g. β-lactam antibiotics,
aminoglycosides, and fluoroquinolones), later infections are more difficult to treat as antibiotic
resistance emerges with the patient’s age [8]. Resistance develops under the pressure of continued
heavy use of antibiotics and is linked to increased occurrence of hypermutable P. aeruginosa
isolates [47]. The emergence of these isolates is associated with the ongoing oxidative stress
caused by the chronic polymorphonuclear leukocyte inflammation typical of many CF patients
[48]. Thus, a novel antibiotic with a dual anti-inflammatory function may prove useful for
treating and preventing additional exacerbations of CF airway disease.
Previous cationic sterol-based cationic lipids synthesized by our laboratory,
dexamethasone spermine (DS)[23] and disubstituted dexamethasone spermine (D2S)[49],
exhibited dual antimicrobial and anti-inflammatory functions. This study presents the synthesis
and characterization of six new cationic steroids of similar structure to further understanding of
this family of compounds. Instead of dexamethasone (dex), the six novel lipids presented (Figure
3.1) here contain other glucocorticoids (GCs) as the steroidal side groups: beclomethasone in BeS
and Be2S, budesonide in BuS and Bu2S, and flumethasone in FS and F2S. These cationic lipids
were the result of linking a polyamine, i.e. spermine, to the 21-OH position of each steroid.
Products from this linkage reaction were either monosubstituted or disubstituted, with linkages
occurring at one or both terminal amino groups of spermine, respectively. Compounds were
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evaluated for glucocorticoid, antimicrobial, and DNA lipofection activities, as well as for any
potential cytotoxic effects on mammalian cells.

Figure 3.1: Structures, molecular weights, and CLogP values of FS, F2S, BuS, Bu2S, BeS, and Be2S.
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3.3 Materials and Methods
3.3.1 Synthesis of Beclomethasone-21-mesylate and Flumethasone-21-mesylate
A 125-mL Erlenmeyer flask was filled with 1 g of the desired GC, 3.2 mL of anhydrous
pyridine, and 240 µL of methanesulfonyl chloride. The flask was kept at 0°C with an ice bath and
stirred continuously with a magnetic stir bar. After 1 hour, an additional 160 µL of
methanesulfonyl chloride was added and an additional hour was allowed to elapse. The solution
was then poured into 20 mL of ice-cold 1 M HCl, causing precipitation. The solid was filtered out
and then re-dissolved into 50 mL of ethanol. Precipitation was facilitated again by pouring the
solution into 50 mL of 1 M HCl. The precipitate was filtered out one last time, recrystallized in
ethanol, filtered, and dried overnight before further processing.
3.3.2 Synthesis of Cationic Glucocorticoids
BeS, Be2S, BuS, Bu2S, FS, and F2S were prepared using a reaction scheme previously
described for the synthesis of DS and D2S [23]. Briefly, the 21-mesylate form of each steroid was
reacted separately into its mono- and di-substituted cationic products via a one-pot reaction
involving molar excesses of both spermine and Traut’s reagent (2-iminothiolane HCl) in ethanol
at 40°C. Beclomethasone-21-mesylate and flumethasone-21-mesylate were synthesized as
described earlier, and budesonide-21-mesylate was obtained from Steraloids (Newport, RI).
Spermine and Traut’s reagent were obtained from Sigma-Aldrich. The reaction was allowed to
proceed for ~1 hour before being quenched with trifluoroacetic acid (Sigma-Aldrich). Ethanol
was removed through evaporation under vacuum, and the reaction products were dissolved in
water before the purification process.
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3.3.3 Semi-preparative Purification of Reaction Products
A Shimadzu (Columbia, MD) LC-MS system was used to purify desired products from
the crude reaction mixture. This system included an LC-20AB pump for solvent delivery
connected to a SIL-20A autosampler, which was coupled to a SPD-20A for dual wavelength UVVis detection and a LCMS 2010EV mass spectrometer. A Hamilton (Reno, NV) PRP-1 column
(250 x 10 mm i.d., 10- µm particle size) was used with this LC-MS to facilitate separation. The
mobile phase flow rate was 4 ml/min with a starting ratio 95% mobile phase A (water) and 5%
mobile phase B (acetonitrile). For the beclomethasone- and flumethasone-derived products, the
elution profile consisted of an isocratic step to 13% phase B for 35 minutes and then another
isocratic step to 20% phase B for an additional 35 minutes. For separation of the budesonide
products, the first step of the elution profile is the same at 13% phase B for 35 minutes, but the
second step uses 25%, in lieu of 20%, phase B for the same amount of time. Solvent from
collected fractions was removed via lyophilization, and final products were resuspended in
nuclease-free water at concentrations between 10 and 20 mg/ml.
3.3.4 Analytical Characterization
Analytical characterization was performed with the same Shimadzu LC-MS system
coupled to a Hamilton PRP-1 column (150 x 4.6 mm i.d., 5- µm particle size). The mobile phase
flow rate was 1 ml/min with a starting composition of 95% mobile phase A (water) and 5%
mobile phase B (acetonitrile). The elution profile for the beclomethasone- and flumethasonederived products consisted of an isocratic step to 13% phase B for 25 minutes and then a second
step to 20% phase B for an additional 25 minutes. For the budesonide-derived products, the
second step utilized 25% phase B. Results from the mass spectrometer was used to assess purity
of eluent. 1H and 13C NMR analyses were performed using an AVANCE III 500 MHz
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instrument (Bruker, Newark, DE) using a dual 5-mm cryoprobe. The calculated log values of the
octanol/water partition coefficient, i.e. ClogP values, were predicted with ChemBioDraw Ultra
software (Cambridgesoft) using fragmentation methods.
3.3.5 Cell Culture
Bovine aortic endothelial cells (BAECs) and A549 cells were cultured at 37°C and 5%
CO2 in DMEM supplemented with 10% FBS, 2% penicillin/streptomycin, and 1% L-glutamine
(all materials from Gibco, Life Technologies). All experiments were conducted with cells seeded
24 hours before any treatment at 50-75% confluence in 96-well plates.
3.3.6 Nuclear Localization of the Glucocorticoid Receptor
Ability to trigger nuclear localization of the GC receptor (GR) was visualized by
transfecting BAECs with pGFP-GR, a plasmid encoding for a green fluorescent protein (GFP)GR chimeric protein. Cells were seeded as described earlier and allowed to spread overnight.
Transfections were then conducted with Lipofectamine 2000 (Life Technologies), according to
the manufacturer’s instructions. DNA-Lipofectamine complexes were incubated with cells for
two hours before the growth media was replaced with DMEM supplemented with 0.5% charcoaltreated FBS to prevent non-specific cellular responses to hormones in the serum. After an
additional overnight incubation, cells were treated with cationic GCs at the specified
concentrations (0.01 -1 μM) for approximately 1 hour before being imaged using light and
fluorescence microscopy (IX81; Olympus America). Total cellular fluorescence and nuclear
localized fluorescence were calculated with ImageJ (NIH) for at least 10 cells per condition.
These values were used to determine the average percentage of nuclear localized cellular
fluorescence per condition.
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3.3.7 Induction of the Glucocorticoid Response Element
Ability to induce the GC transcriptional response element (GRE) was analyzed by
transfecting BAECs with pGRE-SEAP, a plasmid containing the gene for a secreted embryonic
alkaline phosphatase (SEAP) under transcriptional control of the GRE. BAECs were transfected
using the procedure described earlier for pGFP-GR transfection. After replacement of the media
with DMEM containing 0.5% charcoal-treated FBS, cells were incubated overnight. Growth
media was then refreshed with fresh media containing the specified concentrations of the
synthesized cationic lipids (1 or 5 μM). Cells were treated with the lipids for 24 hours before the
media was harvested and stored at -20°C until further processing for SEAP quantification, which
was conducted using the Great EscAPe™ SEAP Chemiluminescence Reporter Kit 2.0 (Clontech)
according to the manufacturer’s instructions. Chemiluminescence was measured with an
EnVision Multilabel Plate Reader (PerkinElmer Life and Analytical Sciences, Waltham, MA).
3.3.8 Antibacterial Activity
Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations
(MBCs) were determined using bacteria in their logarithmic phase of growth. Compounds were
tested against the following bacteria: MRSA strain Xen30 (Caliper Life Sciences), Escherichia
coli, and various strains of Pseudomonas aeruginosa, i.e. PA14, Xen5 (Caliper Life Sciences),
and ten clinical strains isolated from CF sputum. Clinical strains were collected by spontaneous
expectoration from patients attending the Adult Cystic Fibrosis Center, University of
Pennsylvania Health System (IRB 803255). When necessary, samples were diluted with PBS and
vortexed in the presence of glass beads to produce homogenous solution. Known antimicrobial
agents tobramycin (TOB), cathelicidin LL-37 (Peptide 2.0), DS, and D2S, were also tested to
provide reference MIC and MBC values. MIC/MBC values were determined in Luria-Burtani
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(LB) media using the microdilution methods. Bacteria were incubated at 37°C for 18-24 hours
before being treatment. MIC values were determined against bacterial concentrations of ~5 x 105
CFU/ml, and MBC values were performed by plating each sample on appropriate solid agar
mediums.
3.3.9 Preparation of Liposomes and Lipoplexes
Liposomes were formed by combining lipids with a neutral lipid, 1,2-dioleoyl-snglycero-3-phosphoethanolamine (Avanti Polar Lipids) in a 1:1 molar ratio, as previously
described [49]. Briefly, the neutral lipid in chloroform was added to a glass tube, and the solvent
was removed under vacuum to generate a lipid film. The film was rehydrated with sterile water
containing appropriate amounts of the desired cationic lipids. Mixtures were then probe-sonicated
for 30 seconds and briefly vortexed before use. Lipoplexes were formed by diluting the liposomes
into an equal volume of Opti-MEM® I Reduced Serum Media (Life Technologies) containing
plasmid DNA at the appropriate concentration. Lipoplexes were formed 15 minutes before use in
all experiments.
3.3.10 Transfection and measurement of EGFP
Lipoplexes were used to transfect BAECs and A549 cells, separately, to determine
transfection abilities of synthesized lipids. Plasmid DNA, pGFP-N3 (Clontech), was transfected
to generate GFP as a fluorescent transgene reporter protein. Lipofectamine 2000 in a 2:1 (w/w)
ratio with DNA was used as the positive control for both cell lines, and plasmid DNA without any
cationic lipid was used as the negative control. Cells were transfected in quadruplicate in 96-well
plates, 24 hours post-seeding. Media was removed, and cells were washed once with sterile PBS
before being treated with lipoplexes. After three hours of treatment, media was aspirated and
replaced with fresh DMEM without any antibiotics. After 24 hours, cells were harvested and
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processed with flow cytometry to determine the percentage of cells positive for GFP. A BD
Accuri™ C6 flow cytometer was used for this analysis
3.3.11 Effects on Cell Viability
A549 and BAECs cells were seeded on 96-well plates and allowed to spread overnight,
as described earlier. Growth media was then replaced with media containing specified
concentrations of lipids (0.01 – 50 μM), and cells were incubated for 24 hours. A CellTiter-Glo®
Luminescent Cell Viability Assay (Promega) was then used to evaluate cell viability after
treatment, according to the manufacturer’s instructions. Luminescence was measured with an
EnVision Multilabel Plate Reader Reader (PerkinElmer Life and Analytical Sciences, Waltham,
MA).
3.3.12 Red Blood Cell Hemolysis
Hemolytic activities of synthesized cationic lipids were tested against human red blood
cells (RBCs) collected from fresh blood, obtained in accordance with University of
Pennsylvania’s IRB. Whole blood was anti-coagulated in citrate concentrated solution (9 parts
whole blood to 1 part citrate solution, SigmaAldrich), and then centrifuged for 5 minutes at
500xg. Plasma was removed, and the remaining hematocrit layer was resuspended in 150 mM
NaCl to wash the RBCs. Sample was centrifuged again at 500xg for 5 minutes and then washed
an additional two times, first with 150 mM NaCl and then with fresh Tyrode’s solution without
bovine albumin serum. After a final centrifugation cycle, a ~2% hematocrit suspension was
achieved by diluting 1mL of RBCs into 49mL of fresh Tyrode’s solution. Compounds were
added to 100 µL of this suspension to achieve the specified concentrations, and all samples were
incubated for 1 hour at 37°C before centrifugation at 500xg for 5 minutes to pellet any intact
RBCs. Supernatants were transferred into a clean 96-well plate, and relative hemoglobin (Hb)
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concentration was quantified by measuring absorbance at 405 nm. To achieve 100% hemolysis,
1% Triton X-100 was as a positive control to disrupt RBC membranes.

3.4 Results
A one-pot reaction with the appropriate GC mesylate, Traut’s reagent (TR), and spermine
yielded the monosubstituted steroid (FS, BuS, or BeS) as the major product and the disubstituted
steroid (F2S, Bu2S, or Be2S) as the minor product. The primary amines on either end of spermine
reacted with TR to cause a selective ring-opening, resulting in an exposed sulfhydryl (-SH) end
group. This end group then interacted with the α-keto mesylate of the modified GCs to form an αketo thioether linkage between the steroid and polycation tail (i.e. the spermine-TR conjugate),
yielding the monosubstituted cationic steroid. To form the disubstituted product, the primary
amine of the monosubstituted lipid reacted with another TR molecule to eventually result in
another thioether linkage with a separate GC molecule.
Desired compounds were purified from excess starting reactants and unwanted reaction
intermediates with semi-preparative HPLC, and then their molecular weights and chemical
structures were verified with mass spectroscopy (MS) and 1H and 13C NMR. MS results are
shown in Appendix A, Figures A1-A3. 1H and 13C NMR spectra and chemical shifts are also
shown in Appendix B and Appendix C, Figures B1-B6 and C1-C6, respectively. Overall yield for
the entire process (synthesis to purification) was ~60-70%, i.e. ~60-70% conversion of the parent
steroid mesylate to the monosubstituted cationic product and a subsequent ~6-10% conversion of
the monosubstituted product to the disubstituted product in a one-pot reaction.
Hydrophobicity of compounds was also assessed through ClogP values, which are shown
in Figure 3.1. Disubstituted products exhibited higher CLogP values than their monosubstituted
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analogues. Budesonide-derived compounds showed the highest values, while flumethasone
compounds showed the lowest.
Ability to trigger some degree of nuclear localization of the GR was observed for all
cationic lipids, though some exhibited more potency than others (Figure 3.2). Only budesonidederived compounds showed activity equivalent to that seen with the positive control dex.
Flumethasone and beclomethasone compounds showed less potency than equivalent
concentrations of dex at all values tested (p<0.01). GC character was further evaluated by
measuring ability to induce expression of the GRE. Again, budesonide-derived products are the
only compounds to achieve expression equivalent to that seen with dex (Figure 3.3). Interestingly,
beclomethasone products showed a comparatively limited ability to trigger GRE induction; no
cellular response was observed at 1 µM BeS or Be2S (data not shown). At 5 µM, Be2S trigged
only a modest response, while BeS triggered no effect at all. Flumethasone-derived products were
able to achieve equivalently limited responses at 1 µM for both FS and F2S.
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Figure 3.2: Steroid-induced nuclear localization of GFP-GR in BAECs
(A) GFP-GR translocation from cytosol to nucleoplasm. BAECs were transfected with pGFP-GR using Lipofectamine
2000 and then treated with compounds to stimulate GFP-GR nuclear localization. (B) Quantitative evaluation of
cellular fluorescence localized within the nucleoplasm after treatment. Cells were treated with dexamethasone (positive
control), FS, F2S, BuS, Bu2S, BeS, and Be2S at various concentrations. After 4 hours of treatment, cells were imaged
using fluorescence microscopy, and percentage of cellular fluorescence localized with in the nucleus was assessed
using ImageJ. At least 10 cells per condition were evaluated. Results are presented as means, and error bars represent
the standard deviation. All experimental compounds showed some degree of GC activity greater than the untreated
control at all concentrations tested (** p<0.01, Student’s t-test). Only BuS (0.1-1 μM) and Bu2S (0.01-1 μM), however,
showed activity equivalent to that seen at equivalent concentrations of the positive control dexamethasone. † †
indicates statistical significance (p<0.01, Student’s t-test) when compared to dexamethasone.
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Figure 3.3: Steroid-induced activation of GRE promoter in BAECs
Cells were transfected with pGRE-SEAP using Lipofectamine 2000 and then treated with (A) 1 μM FS and F 2S, (B) 1
μM BuS and Bu2S, and (C) 5 μM BeS and Be2S to induce activation of the GRE-SEAP gene construct. After 24 hours
of treatment, media was harvested and evaluated for SEAP levels. Results were normalized relative to the positive
control, dexamethasone (dex), and are presented as means. Error bars represent the standard deviation. Only BuS and
Bu2S showed GRE activation comparable to that seen with dex. Flumethasone and beclomethasone products, on the
other hand, showed significantly less GRE activation (** p<0.01, Student’s t-test) than that seen with equivalent
concentrations of dex.

Bacteria killing abilities were tested against various strains of bacteria, including several
clinical isolates of P. aeruginosa, and the determined MICs and MBCs, as well as MBC:MIC
ratios, are presented in Tables 3.1A-B. For clarity, MBCs are also presented in a cluster heat map
in Figure 3.4. While generally more effective against the gram-positive bacterium tested (MRSA
Xen30), many of the monosubstituted products were unable to achieve inhibitory effects at
concentrations less than 128 μg/ml with the other bacteria tested. BuS was the exception in this
general trend, showing activity nearly equivalent to that seen with the more potent disubstituted
products. Notably, BuS and all other disubstituted products displayed bactericidal activity greater
than that observed with the positive controls, tobramycin and cathelicidin LL-37. Bu2S showed
the greatest potency of all compounds tested.
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Table 3.1: Minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of selected
steroids against various pathogens.
(A) Specified pathogens were treated with FS, F2S, BuS, Bu2S, BeS, and Be2S as well as known antibiotic compounds,
i.e. tobramycin (TOB), cathelicidin LL-37, DS, and D2S, to provide reference MIC and MBC values. Concentrations
are in μg/ml. (B) Calculated MBC:MIC ratios. Single daggers (†) indicate ratios that could not be determined because
the MBC and MIC values were both >256 μg/ml (i.e. determined without an exact value). Clinical isolates of P.
aeruginosa (PA) in both tables are indicated by a single asterisk (*)
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Figure 3.4: Cluster heat map of minimal bactericidal concentrations (MBCs, μg/ml) of cationic steroids against
various pathogens.
Specified pathogens were treated with FS, F2S, BuS, Bu2S, BeS, and Be2S as well as known antibiotic compounds, i.e.
tobramycin (TOB), cathelicidin LL-37, DS, and D2S, to provide reference MBC values. Results are presented in a
cluster heat map to visually associate compounds with similar activities. Patterned boxes indicate compound/pathogen
combinations that were not determined (ND). Clinical isolates of P. aeruginosa (PA) are indicated by a single asterisk
(*).

Transfection activities of cationic lipids were assessed using mixtures of varying
monosubstituted to disubstituted lipid ratios on BAECs or A549 cells. Results are shown in
Figure 3.5. With either cell type, transfection mixtures containing only monosubstituted lipids
showed zero to very little transfection activity. Mixtures containing only disubstituted products
achieved transfection activity generally comparable to that seen with the positive control,
Lipofectamine 2000. Interestingly, 60/40 and 40/60 mol% FS/F2S mixtures showed activity
equivalent to that seen with 100% F2S with either cell type. For budesonide and beclomethasone
compounds, trends in activity appeared to be cell specific. 40/60 mol% mono/disubstituted
mixtures appeared more effective with BAECs, while 60/40 mol% mixtures were more effective
with A549 cells.
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Figure 3.5: Transfection of BAECs and A549 cells with FS, F2S, BuS, Bu2S, BeS, and Be2S using GFP transgene
(A) BAECs and (B) A549 were transfected with cationic lipids at a charge ratio of 6:1 or Lipofectamine 2000 (i.e.
Lipo2000, positive control) at a ratio of 2:1(w/w) ratio with DNA. Cells were harvested 24 hours later and sorted for
GFP-positivity using flow cytometry. Results are represented as means, and error bars show the standard deviation
from four replicates of 500-1000 events per condition.

Compounds showed limited toxicity on BAECs and A549 cells at concentrations less
than 50 μM (~30 μg/ml for monosubstituted compounds, ~60 μg/ml for disubstituted
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compounds), as shown in Figure 3.6. At these lower concentrations, loss in cell viability was
never greater than ~10% for BAECs and ~20% for A549 cells. Furthermore, toxic effects on
viability never exceeded that which was seen with dex at equivalent concentrations. At 50 μM,
however, much more dramatic effects were observed. Treatment with any disubstituted
compound resulted in a dramatic loss in cell viability (85-100%) with either cell type. This degree
of toxicity was not observed at 50 μM dex, although this concentration proved to be more toxic
than lesser concentrations of the compound. Interestingly, monosubstituted products also did not
exhibit this amount of cytotoxicity at 50 μM concentration. BuS treatment showed loss in
viability comparable to that seen with dex at this concentration, while FeS and BeS barely caused
a ~5-10% loss in viability.

Figure 3.6 Cell viability post-treatment with FS, F2S, BuS, Bu2S, BeS, and Be2S.
(A) BAECs and (B) A549 cells were treated with cationic lipids at the specified concentrations for 24 hours before cell
viability was assessed. Results represent means, and error bars indicated standard deviation from four replicates at each
condition. At concentrations below 50 μM, compounds showed limited toxicity, i.e. no more than 10% or 25% loss in
viability with BAECs or A549 cells, respectively. Disubstituted products showed significant toxicity at 50 μM only,
resulting in complete or near complete loss in viability with both cell types. In all other cases, toxicity was never
greater than that observed with the dexamethasone control. ** indicates statistical significance (p < 0.01, Student’s ttest) when compared to untreated control.
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Toxicity toward eukaryotic cell membranes was assessed by measurement of Hb release
from human RBCs, and results are shown in Figure 3.7. Significant Hb release was observed only
with the higher concentrations (≥50 μM) of the disubstituted compounds. Bu2S caused the most
Hb release at these concentrations, i.e. ~17% Hb release at 50 μM and ~36% release at 100 μM,
while Be2S resulted in the least, i.e. 0% release at 50 μM and ~8% release a 100 μM. All
monosubstituted products failed to cause >1% Hb release at all concentrations tested.

Figure 3.7: Red blood cell lysis in response to treatment with FS, F2S, BuS, Bu2S, BeS, and Be2S
Freshly isolated human RBCs were treated with specified amounts of cationic lipids, and hemoglobin (Hb) release was
measured after one hour of treatment at 37°C. Results are represented as means, and error bars show the standard
deviation from four replicates at each condition. Monosubstituted products show very little to no RBC hemolysis at all
concentrations tested. Disubstituted products show hemolysis at concentrations greater than 50 μM.

3.5 Discussion
This report presents the synthesis and in vitro characterization of six novel cationic GCs
with dual antimicrobial and anti-inflammatory character. These compounds are based on
previously synthesized sterol-derived cationic steroids, DS and D2S, which also displayed
antimicrobial and anti-inflammatory properties. Compounds presented here exhibited a range of
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anti-inflammatory and antimicrobial activities without showing dramatic toxicities at the
concentrations necessary to achieve desired activities.
Disubstituted products generally demonstrated more potency than their monosubstituted
analogue in many of the categories tested. This is an expected observation since the disubstituted
products, as demonstrated by their CLogP values, are more lipophilic than their monosubstituted
analogues. With higher hydrophobic character, these compounds are able to penetrate the
hydrophobic core of a cell membrane more easily and trigger the appropriate response once inside
the cell. This enhanced membrane activity is also reflected in their ability to trigger Hb release
from RBCs at concentrations that triggered no such response with the monosubstituted products.
Additionally, the greater anti-inflammatory activity of the disubstituted compounds can also be
attributed to the presence of two steroidal side groups, rather than one. With an additional ligand
to bind appropriate receptors, these compounds are more likely to bind and activate the cytosolic
GR once they have bypassed the cell membrane.
Interestingly, at concentrations above 0.01 μM, one monosubstituted compound, BuS,
was able to achieve levels of GC activity equivalent to that observed with dex and its
disubstituted counterpart (Bu2S) without demonstrating significant membrane disruption activity.
At the concentrations tested (0-100 μM), treatment of RBCs with BuS did not cause any Hb
release, indicating that the plasma membrane had not been compromised. Together, these
phenomena suggest that BuS is membrane permeable without being membrane disruptive, as it
must bypass the cell membrane in order to bind the cytosolic GR for GC activity. Likely, the
smaller size of BuS, relative to that of the disubstituted compounds, allows it to pass through the
membrane without disrupting the structural integrity.
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GC activity is also known to correlate with the size and polarity of the substituent at the
16 position [50]. Hydrophobic residues at this position, like the cyclic butryaldehyde-containing
acetal group of budesonide, result in higher GC potency. In fact, unmodified budesonide
demonstrates GC activity that is ~10 times more potent than that of dex [50] and a GR affinity for
that is ~8 times the GR affinity of dex [51]. Unmodified flumethasone and beclomethasone have
GC activities that are only 2-3 times higher than GC activity of dex [50]. Consequently, the
comparatively high degree of GC activity of BuS and Bu2S is not particularly surprising.
However, the lack of GC activity from flumethasone- and beclomethasone-derived compounds is.
This effect suggests that addition of the cationic tails to these steroids either results in decreased
membrane permeability or decreased GR affinity. The fact that BuS, a monosubstituted analogue,
is able to effectively trigger GC activity suggests that this effect is not due to a loss in membrane
permeability. FS and BeS are likely just as able to penetrate the cell membrane but are ultimately
unable to bind the GR without sufficient affinity for activation.
The trends observed in bacteria killing ability are generally analogous to those seen with
GC activity. The disubstituted compounds are more effective than their monosubstituted
counterparts, and the explanations are likely the same, despite the differences in lipid membrane
constituents in prokaryotic and eukaryotic cells. Disubstituted compounds are larger and more
hydrophobic, enabling them to more easily associate with a lipid bilayer membrane and cause
disruptions in the structural integrity when they do so. Notably, however, BuS once again shows
unexpectedly high activity. Despite being less effective than its disubstituted counterpart, it was
much more effective than any of the other monosubstituted compounds tested. In fact, the
antimicrobial activity of BuS was more comparable to that of the disubstituted compounds than
that of the monosubstituted ones. BuS is thus a particularly promising candidate for a future
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therapeutic because it exhibits high potencies in GC and antimicrobial activity but little in
cytotoxic and hemolytic activity.
Results from the bacteria killing assay also demonstrated two other key findings. First,
BuS and all disubstituted compounds tested were generally more effective at killing the tested
pathogens than antimicrobial compounds cathelicidin LL-37 and tobramycin were, and the latter
is frequently used to treat bacterial infections during CF airway exacerbations. Second, all
compounds of this study, both mono- and disubstituted, showed particularly high efficacies
against the Gram-positive bacterium MRSA Xen30. Gram-positive bacteria are generally more
susceptible to cationic lipids [52], but they may show especial susceptibility with cationic
antibiotics because of their peptidoglycan outer layer. Anionic polymers, i.e. teichoic acids, are
exposed on the surface of Gram-positive bacteria and thread through their peptidoglycan outer
layer. They impart to it a negative charge that facilitates easy association with cationic antibiotics.
Gram-negative bacteria, on the other hand, have an outer membrane layer that contains LPS
molecules, which reduce the fluidity, and thus the permeability, of the membrane. LPS typically
allows resistance against hydrophobic antibiotics for this reason, but the antibiotics presented
here are also cationic in nature. This characteristic likely enables them to weaken the LPS
structure by displacing the divalent cations (Ca2+ and Mg2+) that normally stabilize it, thereby
allowing permeabilization of the outer membrane that render the bacteria unviable.
Transfection activity of the cationic steroids was also assessed, and while no compound
was more efficacious than the commercially available Lipofectamine 2000, many of the
formulations tested showed comparable activity. Those formulations could therefore be used to
facilitate equivalent gene transfer while also effecting anti-inflammatory and antimicrobial
changes as well. The value of these compounds is not in enhancing any single particular effect
but in achieving simultaneous actions with a single formulation.
51

The compounds presented here offer a unique advantage in treating infections associated
with elevated tissue inflammation. As novel antibiotics with dual anti-inflammatory and
bactericidal activities, they are able to treat the infection itself as well as the inflammatory
environment that promotes the development of hypermutable bacteria strains and antibiotic
resistance. The abilities of these compounds to facilitate gene transfer provide additional value
with treatments that target the relevant diseases at their genetic source. More notably, however,
the results presented here additionally demonstrate that these compounds can be synthesized with
different parent glucocorticoids to produce cationic steroids that retain their dual functionalities
but achieve potencies that correlate with that of the starting steroid. Synthesis of these lipids can
thus be modified accordingly to tailor potential treatments for a variety of applications and
potencies.
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4.0 Coordinated cationic glucocorticoid treatment with adenoassociated virus gene transfer during acute airway infection
4.1 Abstract
Airway bacterial infections, whether currently on-going or recently resolved, are known
to reduce efficacy of airway gene transfer by certain viral vectors. This effect is particularly
detrimental for the development of genetic therapies for cystic fibrosis airway disease, which is
characterized by chronic infections with opportunistic bacteria and associated inflammation. In
this study, negative effects of infection were partially reversed by coordinating gene transfer with
pre-treatments involving anti-inflammatory and antimicrobial cationic glucocorticoids. These
cationic glucocorticoids, budesonide spermine and disubstituted budesonide spermine, were
formulated into liposomes with a neutral lipid and administered to Pseudomonas aeruginosa
PAO1-infected mice 24 hours before treatment with an adeno-associated virus vector. All mice
treated with cationic liposomes showed higher expression levels of the reporter gene, and one
mouse even showed expression higher than that seen with healthy, uninfected mice. These results
confirm that cationic glucocorticoid treatment can be coordinated with gene therapies for CF
airway diseases to regain gene transfer efficiency that was lost due the presence of infection.
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4.2 Introduction
As discussed earlier, infections negatively impact gene transfer in the airway, regardless
of whether they are currently on-going or recently resolved at the time of gene administration,
and the mechanism behind this observed effect was linked to the immune response occurring at
the time of gene delivery [53]. These observed phenomenon have strong implications for
potential gene therapies of CF airway disease, a condition characterized by on-going infection
and concomitant inflammation. Without first addressing this hostile environment for gene
transfer, successful gene transfer for treating the underlying genetic disease is likely
unachievable. The multifunctional cationic glucocorticoids discussed in chapter 2 have particular
potential for such applications, as they possess anti-inflammatory and antimicrobial activities in
addition to their abilities to facilitate gene transfer.
In this study, treatment with two cationic glucocorticoids, BuS and Bu2S, was
coordinated with AAV-mediated gene transfer in SP-A KO mice transiently infected with P.
aeruginosa PAO1. BuS and Bu2S were the most likely candidates to perform well in vivo due to
their encouraging potencies observed in vitro. These cationic glucocorticoids were formulated
into liposomes with a neutral lipid, DOPE, and then intranasally delivered to mice 24 hours
before AAV administration. Loss in gene expression in pre-treated groups was only a fraction of
that observed in infected, untreated mice. These results confirm that cationic glucocorticoids can
be coordinated with gene therapies of CF airway disease to produce beneficial results.
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4.3 Materials and Methods
4.3.1 Mice
C57BL/6 male mice were purchased from Charles River Laboratories (Wilmington, MA),
while SP-D and SP-A knockout mice [40] were maintained in-house at the University of
Pennsylvania. For all experiments, a group size of at least 3 mice was used for each experimental
cohort. All animals were maintained at the Animal Facility of the Translation Research
Laboratories at the University of Pennsylvania under protocols reviewed and approved by the
University of Pennsylvania’s Institutional Animal Care and Use Committee. Prior to all intranasal
administrations, mice were anesthetized by an intraperitoneal injection of ketamine/xylazine
(70/7 mg/kg).
4.3.2 Preparation of Cationic Liposomes
Separately, BuS and Bu2S were synthesized and combined with neutral lipid DOPE
(Avanti Polar Lipids) in a 1:1 molar ratio to form liposomes, as described earlier. Briefly, the
neutral lipid in chloroform was added to a glass tube, and the solvent was removed under vacuum
to generate a lipid film. The film was rehydrated with sterile water containing appropriate
amounts of the desired cationic lipids. Mixtures were then probe-sonicated for 30 seconds and
briefly vortexed. Liposomes were then diluted 10x into PBS to achieve the appropriate
concentration. Lipids were formulated 30 minutes before use and kept on ice until administration
to animals.
4.3.3 AAV Preparation
The AAV9 vectors flanked with AAV2 inverted terminal repeats (ITRs) contained a
firefly luciferase (ffluc) reporter gene fused to a nucleus localization sequence at the N-terminus
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under the transcriptional control of the cytomegalovirus (CMV)-enhanced chicken-β-actin
promoter. Vectors were produced by the Penn Vector core as previously described [39].
4.3.4 Preparation of PAO1 Inoculum
P. aeruginosa PAO1 was cultured at 37°C in Miller’s Lysogeny Broth (LB) (Mediatech,
Herndon, VA) or on cetrimide agar from Sigma Aldrich. Bacteria were grown overnight in LB at
37°C with shaking at 250 rpm. Approximately 16-18 hours later, the bacteria were diluted into
fresh broth to an optical density (OD) (λ=600nm) reading of 0.1 and were allowed to grow until
mid-logarithmic phase (OD600=~0.4). At that point, the bacteria were harvested and washed once
in phosphate-buffered saline (PBS) before being diluted into fresh PBS at the desired
concentration (controlled by evaluation of optical density at 600 nm).
4.3.5 Airway Infection with PAO1 and Treatment with Cationic Liposomes and AAV
Before challenge, mice were anesthetized intraperitoneally as described earlier. Mice
were then intranasally (i.n.) challenged with a 20-µL bolus (delivered as two 10 µL aliquots, one
into each nostril) with P. aeruginosa PAO1 to achieve approximately 106 CFU/mouse. At 24
hours post-infection, mice received 20 μL of cationic liposomes at specified concentrations. After
an additional 24 hours, mice were i.n. administered 5 × 1010 genome copies (GC) of AAV vector
in 20 µL (10 µL into each nostril).
To evaluate ffluc expression, mice (~20 grams) were anesthetized and suspended before
20 µL of D-luciferin (15 mg/mL) was i.n. administered as two 10 µL aliquots, one into each
nostril. After 5 minutes, mice were imaged for 60 seconds with the IVIS Xenogen imaging
system. Quantification of signal was calculated with the Living Image 2.5.1 software.
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4.3.6 Evaluation of Bacterial Load
Samples of nasal lavage fluid (NLF) were taken from each randomly selected mouse
(n=2-3 per group) at the time of AAV administration to evaluate bacterial load. Mice were
decapitated and a cannula attached to a 1-mL syringe containing 300 µL of sterile PBS was
placed into the tracheal remnant. PBS was then flushed through the nasal passages and collected
through the nares into a 1.5-mL tube. This recovered fluid was used to flush the nasal cavity
another two times, for a total of three flushes. All samples were kept on ice until further
processing. To determine the CFU counts in each sample, 50-microliter aliquots of each sample
were plated on solid selection agar for P. aeruginosa and incubated at 37°C for 16 hours. The
number of colonies was then counted, and the total CFU count of each sample was back
calculated from that number.

4.4 Results
SP-A KO mice were infected with ~106 CFU PAO1 per mouse, treated with cationic
liposomes (50µM BuS/DOPE or 25µM Bu2S/DOPE) 24 hours later, and then finally given
AAV9.ffluc 48 hours after initial infection with PAO1. A randomly selected group of mice (n=23) were tested for bacterial load at the time of AAV administration (Figure 4.1A). Interestingly,
while the BuS/DOPE treated group showed a lower average bacterial load compared to the
untreated group, the difference was not significant. Additionally, the Bu2S/DOPE treated group
showed no difference compared to untreated mice.
Significant differences, however, were observed in reporter gene expression, when
measured with live whole-animal luminescent imaging one week later (n=3, Figure 4.1B).
Although differences were not significant for the BuS/DOPE treated group, mice, on average and
individually, showed higher levels of ffluc expression than that seen in infected, untreated mice.
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Two of these mice showed ~1.5-fold higher expression than infected, untreated mice, and the last
mouse showed ~6-fold higher expression. This high expression value was even two-fold higher
than that seen in the healthy mice. Recovery in gene expression was much more uniform in the
Bu2S/DOPE treated group, and average expression was significantly higher (~1.7-fold) than that
observed in the infected, untreated group (p<0.01, Student’s t-test).

Figure 4.1 Effects of cationic glucocorticoid pre-treatment on AAV9-mediated transduction during acute
Pseudomonas aeruginosa PAO1 respiratory infection in SP-A KO mice
(A) PAO1 colonization in SP-A KO mouse airway with or without cationic liposome pre-treatment. Approximately 106
CFU of bacteria were i.n. delivered to mice, and ~24 hours later, mice were treated with 20 µL of BuS/DOPE or
Bu2S/DOPE cationic liposomes at the specified concentrations. After an additional 24 hours, i.e. 48 hours after initial
infection, bacterial load was measured through harvest of NLF from randomly selected mice. Samples from the
BuS/DOPE-treated group showed the lowest average bacterial load, but differences were not determined to be
significant. Results are shown as means, and error bars represent the standard deviations for n = 2-3mice in each group
(n = 3 for the PBS-treated group and the BuS/DOPE-treated group; n = 2 for the PAO1-only-treated group and the
Bu2S/DOPE-treated group). (B) AAV9-mediated transduction in PAO1-infected SP-A KO mice with or without
cationic liposome pre-treatment. Two days after PAO1 infection (24 hours after cationic liposome treatment) mice were
i.n. dosed with AAV9.ffluc. One week later, mice were imaged for gene expression. Plots show quantification of
luminescence for mouse nasal cavity of each mouse imaged (n=3 for all groups). The PAO1-only-treated group and
Bu2S/DOPE-treated group showed significantly lower signal than the uninfected, PBS-treated mice did (**p<0.01,
p<0.05, Student’s t-test). Importantly, however, expression in the Bu2S/DOPE group, while lower than that of the
uninfected mice, was significantly higher than that seen in the untreated, infected group (i.e. PAO1-only-treated group,
††p<0.01, Student’s t-test). The BuS/DOPE group showed less uniform increases over the PAO1-treated group, and
differences between that or the PBS-treated group were determined to be insignificant.

4.5 Discussion
Coordination of gene therapies for CF airway disease with dual functioning antiinflammatory, antimicrobial cationic lipids could be an effective means for creating viable
genetic therapies of this monogenic disease. These lipids could potentially treat not only the local
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respiratory infection often seen with many CF patients, but they could also potentially address the
concomitant hyperinflammation that so characteristically defines these patients as well. The
preliminary results described here in this study validate the potential of using sterol-based
cationic lipids to enhance potential gene therapies of CF airway disease.
Pre-treatment with BuS/DOPE or Bu2S/DOPE liposomes at 24 hours before AAV
administration during an active PAO1 infection resulted in partial restoration of reporter gene
expression to normal levels seen in uninfected mice. While these differences were not significant
in the BuS/DOPE group, none of the mice in this group showed lower expression than any of the
mice in the untreated, infected group (n = 3 for both groups). Statistical significance could not be
attained due to high variability in expression due to a single high expressing mouse. Notably, this
high expresser displayed reporter gene expression that was two-times greater than that observed
in the healthy group. Thus, while differences were not significant, trends indicate that BuS/DOPE
treatment was beneficial for restoring or even enhancing gene expression to normal levels. Repeat
studies with greater n-values are required to determine true variability of treatment and potential
reasons why such dramatic variability exists.
Interestingly, the Bu2S/DOPE-treated mice did show significantly higher gene expression
than the infected, untreated group. Preliminary analysis of bacterial load, however, showed
limited efficacy of the Bu2S/DOPE liposome to reduce bacterial load at the time of AAV
administration at the concentration tested, i.e. 25 µM (n=2). This was half the concentration used
for the BuS/DOPE formulations, which showed more obvious reduction in bacterial load at 50
µM (n=3). Higher concentrations of Bu2S were not tested due to toxicity observed in vitro 50 µM.
Regardless, the observed results suggest that gene expression can be restored to normal levels
without reducing overall bacterial load. However, our current experimental protocol prevents us
from assessing both bacterial load and gene expression in the same mouse, and with such
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variability in effects, we cannot determine with certainty whether this conclusion is valid. Mice
selected for analysis of gene expression may have had lower bacterial loads than those taken for
bacterial load analysis, thereby skewing the true results. Additional experiments are required to
further investigate these effects with larger n-number.
The results presented here are preliminary in nature, but they show potential in validating
the use of cationic glucocorticoids to enhance gene therapies of CF airway disease. Additional
studies with larger cohorts to determine true significance of events. Importantly, however, all of
the infected mice treated with cationic liposomes showed higher expression than untreated,
infected mice. Future studies should address the mechanism behind this observed effect by more
complete analysis of effects on bacterial load as well as characterization of effects on immune
response at the time of AAV administration.
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5.0 Conclusions and Future Work
5.1 Conclusions
A viable genetic therapy for cystic fibrosis airway disease does not yet exist, despite the
more than 20 years that have elapsed since the discovery of the single gene that causes the
disease. The lack of a convenient animal model to test potential therapies has hindered progress to
a successful approach. The current work addresses this issue by establishing three different mouse
models of airway infection, one chronic and two acute, to study the effects of infection on
potential therapeutic methods. Individually, these models capture different aspects of clinical
manifestations of CF: chronic infection, exaggerated inflammatory responses, and/or less
effective clearance of bacteria from the airway. In each model, efficiency of AAV9-mediated
transduction was decreased by ~2.5- to 3-fold when AAV was administered on day 2 of infection.
Postponing administration of the vector to a later time point gave different results in the chronic
and acute infection models. During the chronic infection, postponement resulted in an even
greater loss in transduction efficiency (~8-fold), while during the acute infection, the result was
the opposite, i.e. partial regain of efficiency was observed. In both cases, loss in efficiency was
linked to immune responses occurring at the time of AAV administration. Notably, the more
dramatic loss in gene expression at day 14 was associated CD4 T cells and IL-17 secretion, which
is associated with stimulation of airway mucus production.
This work is the first to show the negative effects of active infection on AAV-mediated
gene transfer, and the implications are serious. Optimal therapeutic efficacy of gene therapies for
CF airway disease cannot be achieved unless these effects are addressed as part of the treatment.
Previous work in this lab demonstrated that sterol-based cationic lipids could be useful as
adjunctive treatment to potential CF gene therapies. These lipids not only facilitated gene transfer
but also demonstrated both anti-inflammatory and antimicrobial characteristics as well. In this
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study, six additional cationic glucocorticoids were developed and characterized to further
understanding of this family of compounds. Results revealed that lipids exhibited potencies that
correlated to that of the parent glucocorticoid. Additionally, the two lipids that showed the highest
potencies in vitro, BuS and Bu2S, were particularly ideal for applications in treating airway
disease due to the low ratio of systemic to local activity of the parent glucocorticoid, budesonide.
Logically, this work concludes with the evaluation of these cationic glucocorticoids on
reversing the negative effects of infection on AAV-mediated gene transfer. Preliminary results
were encouraging; all mice that received BuS or Bu2S pre-treatment 24 hours before AAV
administration displayed higher gene expression than that seen with infected mice untreated with
lipid. Interestingly, one mouse treated with BuS showed enhanced gene expression over that seen
with healthy mice. Generally, however, restoration of gene expression was only partial. Lipid
treatment was able to reduce the loss in expression by ~25-47% in all other treated mice.

5.2 Future Work
BuS and Bu2S, thus, show strong potential for enhancing AAV-mediated gene transfer in
an infected environment. Additional studies, however, are required to more accurately
characterize these effects and the mechanisms behind them. Experiments need to be repeated with
larger n-value to determine true significance of events. Studies should also include
characterization of the immune response at the time of AAV administration to evaluate any
effects on inflammation. Methods to further enhance the therapeutic value of these coordinated
gene therapies can also be investigated. Such methods could include varying the dosages and
dosing schedule of the administered lipids. Dosages should differ by total concentration as well as
by composition of mono- to disubstituted compounds. Eventually, lipids can also be tested in the
chronic infection models to determine if therapeutic effects are still observed with the changes in
immune response that eventually occur during a sustained infection. Effects of long-term usage
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should also be considered if these compounds will be used to as an ongoing treatment in cases of
chronic infection.
While the present work has focused the application of these cationic glucocorticoids for
enhancing gene therapies of CF, the therapeutic potential of these compounds be extended to
other applications as well. In particular, the dual anti-inflammatory and antimicrobial
functionality are particularly suited for treating infections associated with elevated tissue damage.
Examples include bacterial keratits (bacterial infections of the cornea) and otitis externa
(inflammation or infection of the ear canal). Such conditions benefit from combined
antibiotic/steroid treatment over treatment that only utilized one or the other [54,55]. The
cationic glucocorticoids presented here could provide a useful alternative to current methods by
eliminating the need for a dual-compound therapy for these conditions.
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Appendix

A: Mass spectrometry data for FS, F2S, BuS, Bu2S, BeS, and
Be2S

Figure A1: Structures of FS and F2S with mass spectrometry data showing multiple ionizations.
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Figure A2: Structures of BuS and Bu2S with mass spectrometry data showing multiple ionizations.
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Figure A3: Structures of BeS and Be2S with mass spectrometry data showing multiple ionizations.
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Appendix

B: 1H NMR Data for FS, F2S, BuS, Bu2S, BeS, and Be2S

Figure B1: 1H NMR spectrum of FS
Flumethasone Spermine, FS, N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)-4-((2((6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)thio)butanimidamide
1
H NMR (500 MHz, DMSO-d6 with TMS) δ 9.19 (s, 1H), 8.16 (s, 0H), 7.30 (dd, J = 10.2, 1.5 Hz, 1H), 6.30 (dd, J =
10.1, 1.9 Hz, 1H), 6.12 (s, 1H), 5.69 (ddd, J = 11.4, 6.6, 2.0 Hz, 1H), 5.59 (ddd, J = 11.5, 6.7, 2.0 Hz, 1H), 5.46 (dd, J =
4.7, 1.6 Hz, 1H), 5.11 (s, 1H), 4.17 (td, J = 6.4, 3.1 Hz, 1H), 3.83 (d, J = 16.6 Hz, 1H), 3.44 (d, J = 16.6 Hz, 1H), 3.28
(s, 1H), 3.03 – 2.87 (m, 10H), 2.57 (td, J = 7.1, 2.4 Hz, 2H), 2.48 (dd, J = 19.8, 6.3 Hz, 2H), 2.21 (tt, J = 11.2, 4.3 Hz,
3H), 1.90 (dp, J = 14.9, 7.6 Hz, 6H), 1.73 – 1.62 (m, 5H), 1.55 – 1.47 (m, 1H), 1.50 (s, 3H), 1.51 – 1.41 (m, 1H), 1.12
(ddd, J = 12.2, 8.1, 4.2 Hz, 1H), 0.89 (s, 3H), 0.81 (d, J = 7.3 Hz, 3H).
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Figure B2: 1H NMR spectrum of F2S
Disubstituted flumethasone spermine, F2S, 4-((2-((6R,8R,9S,10R,11R,13R,14R,16S,17S)-6,9-difluoro-11,17dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17yl)-2-oxoethyl)thio)-N-(1-((6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-7-imino-1-oxo-3-thia-8,12,17triazaicosan-20-yl)butanimidamide 1H NMR (500 MHz, DMSO-d6 with TMS) δ 9.10 (s, 1H), 8.19 (s, 0H), 7.29 (dd, J
= 10.2, 1.5 Hz, 1H), 6.30 (dd, J = 10.2, 1.9 Hz, 1H), 5.63 (dddd, J = 48.7, 11.4, 6.7, 1.9 Hz, 1H), 5.37 (s, 1H), 5.01 (s,
1H), 4.22 – 4.15 (m, 1H), 3.82 (d, J = 16.5 Hz, 1H), 3.44 (d, J = 16.5 Hz, 1H), 3.30 (t, J = 7.0 Hz, 1H), 2.84 (dd, J =
16.5, 9.0 Hz, 2H), 2.59 (td, J = 7.1, 2.9 Hz, 1H), 2.58 – 2.41 (m, 1H), 2.23 (ddt, J = 13.8, 7.8, 5.6 Hz, 2H), 1.87 (dp, J =
28.8, 7.4 Hz, 2H), 1.69 (q, J = 12.5, 11.8 Hz, 1H), 1.65 – 1.58 (m, 1H), 1.52 (s, 2H), 1.55 – 1.45 (m, 1H), 1.14 (ddd, J =
12.1, 8.1, 4.1 Hz, 1H), 0.91 (s, 2H), 0.83 (d, J = 7.2 Hz, 2H).
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Figure B3: 1H NMR spectrum of BuS
Budesonide Spermine, BuS N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)-4-((2((6aS,6bR,7R,8aR,8bR,10(R,S),11aS,12aR,12bR) -7-hydroxy-6a,8a-dimethyl-4-oxo-10-propyl1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2oxoethyl)thio)butanimidamide 1H NMR (500 MHz, DMSO-d6 with TMS) δ 9.13 (s, 1H), 8.55 (s, 4H), 7.32 (dd, J =
10.1, 3.1 Hz, 1H), 6.17 (d, J = 10.0 Hz, 1H), 5.93 (s, 1H), 4.81 – 4.72 (m, 1H), 4.30 (d, J = 9.7 Hz, 1H), 3.70 (dd, J =
16.1, 4.6 Hz, 1H), 3.42 (dd, J = 16.1, 8.1 Hz, 1H), 2.90 (dt, J = 24.2, 7.7 Hz, 6H), 2.57 (t, J = 6.7 Hz, 1H), 2.30 (d, J =
13.4 Hz, 1H), 2.00 (dt, J = 19.1, 8.9 Hz, 1H), 1.83 (ddt, J = 32.5, 24.6, 10.5 Hz, 5H), 1.65 – 1.52 (m, 4H), 1.53 (d, J =
7.7 Hz, 1H), 1.38 (s, 2H), 1.32 (ddd, J = 32.3, 16.0, 8.5 Hz, 2H), 1.21 (s, 0H), 1.11 (qd, J = 12.4, 4.6 Hz, 0H), 1.03 (s,
0H), 1.03 – 0.91 (m, 1H), 0.85 (dt, J = 15.7, 7.9 Hz, 4H).
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Figure B4: 1H NMR spectrum of Bu2S
Disubstituted Budesonide Spermine, Bu2S 4-((2-((6aR,6bS,7S,8aS,8bS,10(R,S),11aR,12aS,12bS)-7-hydroxy-6a,8adimethyl-4-oxo-10-propyl-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2d][1,3]dioxol-8b-yl)-2-oxoethyl)thio)-N-(1-((6aS,6bR,7R,8aR,8bR,10(R,S),11aS,12aR,12bR)-7-hydroxy-6a,8adimethyl-4-oxo-10-propyl-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2d][1,3]dioxol-8b-yl)-7-imino-1-oxo-3-thia-8,12,17-triazaicosan-20-yl)butanimidamide 1H NMR (500 MHz, DMSO-d6
with TMS) δ 9.17 (s, 0H), 8.82 (s, 1H), 8.14 (s, 0H), 7.32 (dd, J = 10.1, 3.0 Hz, 1H), 6.17 (dd, J = 10.0, 2.3 Hz, 1H),
5.93 (s, 1H), 5.19 (t, J = 4.9 Hz, 0H), 5.05 (d, J = 7.4 Hz, 0H), 4.81 – 4.73 (m, 1H), 4.64 (t, J = 4.4 Hz, 0H), 4.30 (dp, J
= 9.7, 3.3 Hz, 1H), 3.70 (dd, J = 16.1, 4.9 Hz, 1H), 3.42 (dd, J = 16.1, 7.7 Hz, 1H), 3.29 (t, J = 6.8 Hz, 7H), 2.94 (p, J =
6.6, 5.5 Hz, 2H), 2.59 (q, J = 6.8 Hz, 1H), 2.51 – 2.45 (m, 1H), 2.34 – 2.27 (m, 1H), 2.11 – 1.95 (m, 1H), 1.87 (td, J =
16.7, 16.1, 10.1 Hz, 3H), 1.84 – 1.59 (m, 1H), 1.65 (s, 1H), 1.62 – 1.53 (m, 1H), 1.56 – 1.50 (m, 1H), 1.46 – 1.23 (m,
3H), 1.20 – 1.02 (m, 0H), 0.98 (ddt, J = 25.2, 11.1, 5.4 Hz, 1H), 0.85 (dt, J = 15.5, 7.6 Hz, 3H).
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Figure B5: 1H NMR spectrum of BeS
Beclomethasone Spermine, BeS N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)-4-((2((8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)thio)butanimidamide 1H
NMR (500 MHz, DMSO-d6 with TMS) δ 9.20 (s, 1H), 8.64 (s, 6H), 7.32 (d, J = 10.1 Hz, 1H), 6.24 (dd, J = 10.1, 1.9
Hz, 1H), 6.00 (d, J = 1.9 Hz, 1H), 5.48 (d, J = 4.6 Hz, 1H), 5.36 (s, 1H), 4.35 (q, J = 3.4 Hz, 1H), 3.77 (d, J = 16.5 Hz,
1H), 3.55 (d, J = 16.5 Hz, 1H), 3.29 (t, J = 6.9 Hz, 1H), 2.97 (ddd, J = 10.6, 6.9, 2.7 Hz, 2H), 2.93 (s, 3H), 2.93 – 2.86
(m, 2H), 2.66 (td, J = 11.6, 11.1, 4.2 Hz, 1H), 2.54 (d, J = 7.2 Hz, 1H), 2.52 – 2.42 (m, 2H), 2.36 (dd, J = 13.8, 4.9 Hz,
1H), 2.27 – 2.11 (m, 1H), 1.95 – 1.78 (m, 5H), 1.64 (d, J = 9.2 Hz, 4H), 1.60 – 1.48 (m, 1H), 1.35 (dd, J = 13.9, 2.4 Hz,
1H), 1.14 – 1.02 (m, 2H), 1.00 (s, 2H).
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Figure B6: 1H NMR spectrum of Be2S
Disubstituted Beclomethasone Spermine, Be2S 4-((2-((8R,9S,11R,13R,14R,16R,17S)-9-chloro-11,17-dihydroxy10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2oxoethyl)thio)-N-(1-((8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-7-imino-1-oxo-3-thia-8,12,17triazaicosan-20-yl)butanimidamide 1H NMR (500 MHz, DMSO-d6 with TMS) δ 9.17 (s, 1H), 8.30 (s, 0H), 7.30 (d, J =
10.2 Hz, 1H), 6.22 (dd, J = 10.1, 1.9 Hz, 1H), 5.98 (d, J = 1.8 Hz, 1H), 5.52 (s, 1H), 5.41 (s, 1H), 4.33 (d, J = 3.1 Hz,
1H), 3.76 (d, J = 16.5 Hz, 1H), 3.54 (d, J = 16.5 Hz, 1H), 3.27 (t, J = 6.9 Hz, 1H), 2.82 (dt, J = 14.9, 6.8 Hz, 3H), 2.64
(td, J = 11.2, 4.1 Hz, 1H), 2.56 – 2.40 (m, 2H), 2.38 – 2.30 (m, 1H), 2.25 – 2.08 (m, 1H), 1.85 (dddq, J = 25.5, 19.6,
11.2, 5.5, 4.8 Hz, 4H), 1.60 (s, 3H), 1.51 (td, J = 12.9, 12.5, 5.2 Hz, 1H), 1.32 (dd, J = 13.8, 2.5 Hz, 1H), 1.11 – 0.99
(m, 2H), 0.97 (s, 2H).
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Appendix

C: 13C NMR Data for FS, F2S, BuS, Bu2S, BeS, and Be2S

Figure C1: 13C NMR spectrum of FS
Flumethasone Spermine, FS, N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)-4-((2((6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo
6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)thio)butanimidamide
13
C NMR (126 MHz, DMSO-d6 with TMS) δ 206.96 (16), 184.38 (1), 166.98 (30), 163.02 (6), 162.91 (6), 151.86 (3),
129.02 (2), 119.42 (5), 119.32(5), 100.75 (24), 99.35 (24), 90.87 (14), 87.53 (7), 86.10 (7), 70.4 4(22), 70.16 (22),
48.14 (26), 48.12 (26), 47.97 (26), 47.94 (26), 47.52 (19), 46.15 (41, 44), 44.19 (46), 43.90 (39), 42.92 (10), 39.05 (12),
38.43 (18), 36.19 (37), 35.81 (31), 34.69 (11), 33.89 (21), 33.75 (21), 32.23 (8), 32.14(8), 32.08 (8), 31.99 (8), 31.69
(9), 31.61 (9), 30.41 (33), 26.34 (47), 24.02 (38), 23.79 (32), 22.76 (27), 22.73 (42, 43), 22.65 (27), 16.67 (20), 15.12
(13).
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Figure C2: 13C NMR spectrum of F2S
Disubstituted-flumethasone spermine, F2S, 4-((2-((6R,8R,9S,10R,11R,13R,14R,16S,17S)-6,9-difluoro-11,17dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17yl)-2-oxoethyl)thio)-N-(1-((6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-7-imino-1-oxo-3-thia-8,12,17triazaicosan-20-yl)butanimidamide 13C NMR (126 MHz, DMSO-d6 with TMS) δ 206.94 (16, 64), 184.37 (1, 49),
166.96 (30, 78), 163.79 (6,54), 163.00 (6,54), 162.89 (6,54), 151.83 (3, 51), 129.03 (2, 50), 119.42 (5,53), 119.32
(5,53), 100.75 (24,72), 99.34 (24,72), 90.87 (14, 62), 87.52 (7,55), 86.09 (7,55), 70.45 (22,70), 70.16 (22,70), 48.14
(26,74), 48.11 (26,74), 47.96 (26,74), 47.93 (26,74), 47.53 (41,44), 46.95 (19,67), 44.61 (39, 46), 42.92 (10, 58), 39.60
(37, 48), 39.43 (12,60), 38.42 (18, 66), 35.82 (31, 79), 34.69 (11, 59), 33.89 (21,69), 33.74 (21,69), 32.23 (8,56), 32.14
(8,56), 32.08 (8,56), 31.99 (8,56), 31.68 (9,57), 31.61 (9,57), 30.39 (33, 81), 26.35 (38, 47), 24.98 (32, 80), 24.05 (42,
43), 22.76 (27,75), 22.71 (27,75), 16.67 (20, 68), 15.12 (13, 61).
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Figure C3: 13C NMR spectrum of BuS
Budesonide Spermine, BuS N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)-4-((2((6aS,6bR,7R,8aR,8bR,10(R,S),11aS,12aR,12bR)-7-hydroxy-6a,8a-dimethyl-4-oxo-10-propyl1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2oxoethyl)thio)butanimidamide 13C NMR (126 MHz, DMSO-d6 with TMS) δ 205.38 (22), 203.73 (22), 185.05 (2),
170.13 (4), 170.04 (4), 166.89 (46), 163.10 (46), 156.33 (6), 127.09 (1), 127.06 (1), 121.67 (3), 121.61 (3), 107.10 (27),
103.46 (27), 98.75 (20), 98.17 (20), 81.86 (18), 80.84 (18), 68.07 (16), 68.02 (16), 55.00 (12), 52.04 (13), 49.35 (13),
46.36 (14), 45.40 (14), 44.35 (37, 40), 44.11 (5), 43.60 (42), 40.18 (15), 39.93 (44), 39.59 (23), 37.57 (47), 37.29
(37.29), 36.41 (28), 36.34 (28), 34.49 (28), 33.81 (10), 33.44 (10), 32.92 (17), 32.19 (17), 31.63 (8), 31.11 (8), 30.54
(49), 30.49 (49), 29.89 (11), 26.16 (43), 26.11 (43), 24.37 (48), 24.14 (48), 23.14 (38, 39), 20.72 (9), 20.68 (9), 17.30
(21), 17.06 (21), 16.78 (29), 16.37 (29), 13.84 (30), 13.77 (30).
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Figure C4: 13C NMR spectrum of Bu2S
Disubstituted Budesonide Spermine, Bu2S 4-((2-((6aR,6bS,7S,8aS,8bS,10(R,S),11aR,12aS,12bS)-7-hydroxy-6a,8adimethyl-4-oxo-10-propyl-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2d][1,3]dioxol-8b-yl)-2-oxoethyl)thio)-N-(1-((6aS,6bR,7R,8aR,8bR,10(R,S),11aS,12aR,12bR)-7-hydroxy-6a,8adimethyl-4-oxo-10-propyl-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2d][1,3]dioxol-8b-yl)-7-imino-1-oxo-3-thia-8,12,17-triazaicosan-20-yl)butanimidamide 13C NMR (126 MHz, DMSO-d6
with TMS) δ 205.35 (22,78), 203.70 (22,78), 185.02 (2,58), 170.07 (4,60), 169.98 (4,60), 166.83 (46,52), 166.76
(46,52), 162.87 (46,52), 156.32 (6,62), 156.28 (6,62), 127.09 (1,57), 127.05 (1,57), 121.67 (3,59), 121.61 (3,59),
107.10 (27,83), 103.46 (27,83), 98.75 (20,76), 98.17 (20,76), 81.86 (18,74), 80.83 (18,74), 68.08 (16,72), 68.02
(16,72), 67.96 (16,72), 67.90 (16,72), 54.99 (12,68), 54.96 (12,68), 52.05 (13,69), 49.35 (13,69), 46.36 (14,70), 46.08
(14,70), 45.39 (37,40), 44.12 (5, 61), 43.59 (35,42), 40.10 (15,71), 39.93 (33,44), 39.59 (23,79), 37.55 (47,53), 37.28
(47,53), 36.42 (28,84), 34.50 (28,84), 33.80 (10,66), 33.45 (10,66), 32.91 (17,73), 32.19 (17,73), 31.57 (8,64), 31.12
(8,64), 30.55 (49,55), 30.49 (49,55), 29.90 (11,67), 26.14 (34,43), 26.08 (34,43), 23.97 (48,54), 22.70 (38,39), 20.71
(9,65), 20.68 (9,65), 17.29 (21,77), 17.05 (21,77), 16.78 (29,85), 16.38 (29,85), 13.83 (30,86), 13.76 (30,86).
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Figure C5: 13C NMR spectrum of BeS
Beclomethasone Spermine, BeS N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)-4-((2((8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo
6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)thio)butanimidamide
13
C NMR (126 MHz, DMSO-d6 with TMS) δ 207.78 (20), 185.34 (3), 167.04 (5), 166.90 (5), 163.70 (43), 152.91 (1),
128.65 (2), 124.08 (4), 88.44 (19), 85.70 (11), 74.20 (15), 49.77 (6), 48.59 (13), 46.46 (33, 36), 46.31 (12), 44.30 (31),
44.03 (38), 42.91 (17), 40.96 (40), 40.11, 39.78 (44), 36.30 (14), 35.94 (29), 34.18 (10), 33.96 (16), 31.77 (46), 30.25
(21), 29.98 (8), 27.63 (9), 26.46 (39), 24.44 (23), 24.24 (45), 24.03 (30), 23.00 (34,35), 22.93 (34,35), 20.17 (25), 17.81
(26).
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Figure C6: 13C NMR spectrum of Be2S
Disubstituted Beclomethasone Spermine, Be2S 4-((2-((8R,9S,11R,13R,14R,16R,17S)-9-chloro-11,17-dihydroxy10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2oxoethyl)thio)-N-(1-((8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-7-imino-1-oxo-3-thia-8,12,17triazaicosan-20-yl)butanimidamide 13C NMR (126 MHz, DMSO- d6 with TMS) δ 207.79 (20, 73), 185.33 (3, 56),
167.02 (5,58), 166.88 (5,58), 165.14 (43, 49), 152.91 (1, 54), 128.65 (2,55), 124.08 (4, 57), 88.42 (19, 72), 85.69
(11,64), 74.20 (15, 68), 49.77 (6, 59), 48.57 (13,66), 46.79 (33, 36), 46.47 (12, 65), 44.53 (31, 38), 42.91 (17, 70),
40.97 (29, 40), 39.78 (44, 50), 35.93 (14, 67), 34.18 (16, 69), 33.96 (10, 63), 31.75 (46, 52), 30.22 (21, 74), 29.98 (8,
61), 27.63 (9, 62), 26.48 (30, 39), 24.89 (45,51), 24.44 (23, 76), 23.87 (34, 35), 20.17 (25, 78), 17.81 (26, 79).
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